Review

Interventions Including Smart Technology Compared With Face-to-face Physical Activity Interventions in Older Adults: Systematic Review and Meta-analysis

Cassandra D'Amore^{1*}, BSc (Hons); Julie C Reid^{1*}, PT, PhD; Matthew Chan¹, MScPT; Samuel Fan¹, MScPT; Amanda Huang¹, MScPT; Jonathan Louie¹, MScPT; Andy Tran¹, MScPT; Stephanie Chauvin², MSc; Marla K Beauchamp^{1,3,4}, PT, PhD

¹School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada

²Department of Physical Therapy, University of Toronto, Toronto, ON, Canada

³Department of Medicine, McMaster University, Hamilton, ON, Canada

⁴Research Institute at St Joseph's Healthcare, Hamilton, ON, Canada

*these authors contributed equally

Corresponding Author:

Marla K Beauchamp, PT, PhD School of Rehabilitation Science McMaster University 1400 Main Street West Institute for Applied Health Sciences Building Hamilton, ON, L8S 1C7 Canada Phone: 1 905 525 9140 ext 21732 Fax: 1 905 524 0069 Email: <u>beaucm1@mcmaster.ca</u>

Abstract

Background: This is a systematic review of randomized controlled trials and a meta-analysis comparing smart technology with face-to-face physical activity (PA) interventions in community-dwelling older adults (mean age 60 years).

Objective: This study aims to determine the effect of interventions including smart technology components compared with face-to-face PA interventions on PA and physical function in older adults. The secondary outcomes are depression, anxiety, and health-related quality of life.

Methods: We searched MEDLINE, Embase, CINAHL, and AMED electronic databases from inception to February 2021. Two independent reviewers screened titles, abstracts, and full texts and performed data extraction and risk of bias assessments using the Cochrane risk of bias tool. The Grading of Recommendations Assessment, Development and Evaluation was used to evaluate the quality of the evidence. We provided a narrative synthesis on all included studies and, where possible, performed meta-analyses for similar outcomes.

Results: This review included 19 studies with a total of 3455 participants. Random effects meta-analyses showed that interventions with smart technology components resulted in improved step count (mean difference 1440 steps, 95% CI 500-2390) and total PA (standardized mean difference 0.17, 95% CI 0.02-0.32) compared with face-to-face alone. There was no difference between groups in terms of the measures of physical function. Smart technology alone did not show significant differences between groups in any outcome. The quality of the evidence was very low based on the Grading of Recommendations Assessment, Development and Evaluation criteria.

Conclusions: Interventions that include smart technology may improve daily step counts by an average of 1440 steps in community-dwelling older adults; however, the quality of the evidence was very low. Future studies are needed to improve the certainty of these results.

Trial Registration: PROSPERO CRD42020135232; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=135232

(J Med Internet Res 2022;24(10):e36134) doi: 10.2196/36134

KEYWORDS

aging; exercise; mobile health; mHealth; wearables; mobile phone

Introduction

Background

In 2017, the global population of adults aged ≥ 60 years was 962 million, more than twice the number of older adults in 1980 [1]. By 2050, it is expected that the number of older adults will double, reaching nearly 2.1 billion [1]. As the population ages, delaying the onset of illness and disability and retaining physical function are top public health priorities [2]. Physical activity (PA), defined as any bodily movement produced by skeletal muscles that requires energy expenditure [3], is one way to achieve this. However, evidence suggests that 31% of the global population does not meet the recommended levels of PA [4,5], and inactivity has been identified as a leading risk factor for mortality, accounting for >5 million global deaths annually [6]. A recent umbrella review including 24 systematic reviews reported that older adults that are physically active have a lower risk of all-cause and cardiovascular mortality, breast and prostate cancer, fractures, disabilities with activities of daily living, functional limitations, risk of falling, cognitive decline, dementia, Alzheimer disease, and depression [7]. In 2018, the World Health Organization released their global action plan on PA to combat inactivity and improve health over the next decade [8].

In late 2019, SARS-CoV-2, which causes COVID-19 disease, emerged and quickly became an international health crisis, and in March 2020, the World Health Organization declared COVID-19 a global pandemic [9]. Since then, many countries have established strict public health measures to curb the spread of the disease, including social distancing and isolation. Although these measures have the benefit of minimizing viral transmission, which is critical for older adults who are at a higher risk for more severe illness [10,11], they have also exacerbated levels of physical inactivity. A systematic review including 66 studies with nearly 87,000 participants from 26 countries reported significant declines in PA during the lockdown owing to the COVID-19 pandemic [12]. Unfortunately, older adults are also at a higher risk for consequences of inactivity, such as frailty, sarcopenia, and chronic diseases, compared with their younger counterparts [13]. These data highlight an urgent need to evaluate alternative methods of improving PA levels. Fortunately, with advancements in technology, smart technology has become an increasingly relevant and studied tool for achieving health objectives [14,15]. Smart technology interventions may represent an ideal alternative to traditional face-to-face programs as they have the potential to overcome service delivery barriers such as limited access; inconvenience of travel; absenteeism from work and family [16]; and, now importantly, minimizing unnecessary exposure to COVID-19 for those who are most at risk. The role of smart technology in improving PA in older adults warrants further evaluation both now and for informing future directions of health care delivery.

Smart technology capitalizes on communication and information technologies (eg, internet and video calls) [14] and uses different mediums, such as computers and tablets, or mobile health, which includes smartphones, wearables (eg, FitBit), and mobile apps (eg, My Fitness Pal, Samsung Health, and Apple Health) [17]. Systematic reviews have demonstrated that smart technology interventions can improve PA levels, specifically steps per day and minutes per day of moderate to vigorous PA in generally healthy older adult populations (mean age ≥ 55 years) [18-21]. However, there are still unanswered questions and a need for more and better evidence. For example, existing reviews have examined only specific types of smart technology [20] or included only digital PA estimates without considering participant-oriented outcomes [19]. Importantly, existing systematic reviews have not compared smart technology PA interventions with more traditional modes of PA intervention delivery (ie, face-to-face) [15,20-23]. This comparison is essential for determining whether interventions that include smart technology components are more, less, or as effective as face-to-face alone interventions. Therefore, the purpose of this review is to determine the effects of PA interventions that use smart technology compared with face-to-face PA interventions on PA and physical function in community-dwelling older adults.

Review Question

This systematic review will answer whether the PA interventions that use smart technology are more, less, or as effective as face-to-face alone interventions for increasing PA and function in older adults. The secondary questions were as follows: (1) What are the effects of smart technology PA interventions on secondary outcomes, including health-related quality of life (HRQoL), anxiety, and depression? and (2) Does the effectiveness of smart technology interventions differ by type of PA or by the type of smart technology used (eg, wearable vs mobile app)?

Methods

Overview

This systematic review was conducted in accordance with a peer-reviewed protocol [24] registered in PROSPERO (CRD42020135232) and followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines [25]. The full protocol has been published elsewhere [24].

Data Source and Searches

A comprehensive search of the MEDLINE, Embase, CINAHL, and AMED databases from inception to February 2021 was conducted after consultation with a health research librarian [26]. The full search strategies are available in Multimedia Appendix 1 [27-45]; common Medical Subject Headings across databases included age, technology, physical fitness, with keywords to capture all types of PA and smart technology.

Reference lists of included studies were hand searched to identify additional relevant studies.

Study Selection

Overview

Two independent reviewers completed screening for both the titles and abstracts and full-text articles using the web-based referencing software system Covidence (Veritas Health Innovation). Disagreements were resolved by consensus or arbitration by a third reviewer as necessary.

Inclusion Criteria

We included studies that met the following criteria: (1) community-dwelling older adults with a mean age of ≥ 60 years [46], (2) interventions that promoted PA using smart technology, (3) face-to-face interventions in comparator groups, (4) a primary outcome measure of PA or physical function, and (5) randomized controlled trials (RCTs) published in English in a peer-reviewed journal.

Exclusion Criteria

We excluded studies that evaluated participants admitted to an inpatient unit in a hospital or long-term care home, interventions that only used audio phone calls (ie, with no video or SMS text messaging equivalent to the use of a landline), video games, or virtual reality. Studies that used a quasi-experimental design were also excluded.

Data Extraction and Risk of Bias

Data from the included studies were extracted independently and in duplicate using a standardized data collection form [24]. Two reviewers independently assessed studies using the Cochrane risk of bias tool [47] and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [48].

Data Synthesis and Analysis

Meta-analyses for primary and secondary outcomes were conducted using random effects models with standardized mean difference (SMD) and mean difference (MD) where appropriate in Review Manager (RevMan; version 5.4, The Cochrane Collaboration, 2020) [24]. According to the Cochrane handbook, when necessary, we converted scales to correct for the difference in direction [49], and median and IQR were converted following the methods of Wan et al [50]. When possible, we performed sensitivity analyses by removing studies with an overall rating of a high risk of bias for each outcome. This deviates from the initial protocol, wherein we planned to remove only studies with a high risk of bias in \geq 3 domains. Where appropriate, we completed subgroup analyses for our secondary questions. Where possible, we completed analyses for interventions that used smart technology alone compared with face-to-face alone.

Results

Overview

We identified 12,245 records from our search; reviewers screened 9434 titles and abstracts after duplicate removal, and 19 RCTs were eligible for inclusion (Figure 1). The reasons for full-text exclusion are provided in Multimedia Appendix 1. Reviewers attempted to contact 7 corresponding authors for missing information, and 1 author responded. All the studies were combined in a narrative synthesis, evaluating a total of 3455 participants. A total of 18 RCTs with 3405 participants randomized to either a smart technology or face-to-face intervention were included in the quantitative analysis.

Characteristics of the studies are shown in Tables 1-2. Of the 3455 participants, 1874 (54.24%) were female, and the mean age ranged from 60 to 72 years. Studies were conducted at outpatient or community practices in the following countries: United States (6/19, 32%); Belgium (2/19, 11%); Netherlands (2/19, 11%); United Kingdom (2/19, 11%); and one each in Australia, Chile, Denmark, Finland, Hong Kong, New Zealand, and Spain. Participants were community-dwelling older adults, with 14 studies focused on specific clinical populations, including people with chronic obstructive pulmonary disease (COPD) [27-31], cardiovascular disease [32-35], diabetes [36,37], knee arthritis [38,39], obesity [40], and cognitive impairment plus physical frailty [41].



Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flow diagram of evidence search and selection.





D'Amore et al

Table 1. Characteristics of included studies with author names beginning with A to J.

		e	e		
Study and country	Population, sample size (n)	Intervention ^a	Usual care	Outcomes	Key findings
Alonso- Domínguez et al [36], 2019, Spain	T2DM ^b , median age IG ^c =60.8 (IQR 7.8) years; CG ^d =60.4 (8.4) years, 45.6% female, n=204	[Smartphone app] Daily use of mobile app for 3 months + heart-healthy 4-km walks once per week for 5 weeks	10-minute standardized counseling session on PA ^e and healthy diet; in- formation leaflet provid- ed	PA: steps per day mea- sured by pedometer; weekly PA measured by IPAQ ^f -Spanish version	Significant increase in daily steps per day (P<.05 at 3 and 12 months), aerobic steps (P<.05 at 3 months), dis- tance walked $(P<.05 \text{ at } 3 \text{ months})$, and total PA (P<.05 at 3 months) for intervention group
Armit et al [43], 2005, Australia	Community-dwelling older adults (55-70 years), mean age 64 (SD 4.6) years, 64.9% female, n=37 recruit- ed, 28 with 1 assess- ment	[Pedometer] Pedometer use for 12 weeks; counseling session; information book- let; diary for goal setting and self-monitoring; 3 follow-up phone calls to reevaluate, reinforce, and discuss adher- ence issues	Counseling session; infor- mation booklet; diary for goal setting and self- monitoring; 3 follow-up phone calls to reevaluate, reinforce, and discuss adherence issues	PA: self-report survey ^g	No significant difference in PA between groups at either time point
Audsley et al [44], 2020, United King- dom	Community-dwelling older adults from Falls Management pro- gram, mean age IG=76.9 (SD 7.0) years; CG=73.8 (SD 6.4) years, 73.3% fe- male, n=50	[Pedometer] 6 sessions of 60 to 90 minutes of motivation- al interviewing and behavior change techniques over 6 months; pedometer use worksheets with PA diaries + usual care	24-week group exercise program (strength, bal- ance, cardiovascular, and flexibility exercises) + 30-minute 2 times per week home exercise pro- gram; how to get up from a fall and strategies to re- duce inactivity	PA: weekly MVPA ^h measured by Phone- FITT ⁱ questionnaire	No significant differ- ences in MVPA between groups
Barnason et al [32], 2009, United States	Postoperative CABS ^j (aged >65 years), mean age 71.2 (SD 4.9) years, 17% fe- male, n=280	[Telerehabilitation] Tele- health symptom manage- ment for 6 weeks on strate- gies to address common symptoms after CABS and improve outcomes (eg, PA and functioning) + usual care	Usual care not defined	PA: modified 7-day Ac- tivity Interview; activity counts by accelerometer; Physical Activity and Exercise Diary; quality of life: MOS SF-36 ^k	Higher overall energy expenditure in usual care group, except at 3 weeks where intervention group had higher expenditure; no other significant differ- ences
Christiansen et al [38], 2020, United States	Unilateral TKR ¹ (aged >45 years), mean age 67 (SD 7.0) years, 53.4% female, n=43	[Wearable] 6-month stan- dard outpatient PT ^m with a Fitbit Zip, weekly steps per day goal from a PT, 6 monthly phone calls from a research assistant	Standard outpatient PT, including printed home exercise program; 6 monthly phone calls after discharge discussing overall health	PA: steps per day and MVPA per week mea- sured by Actigraph	Increased steps and min- utes per week in MVPA for intervention group at both follow-ups
de Blok et al [27], 2006, Netherlands	COPD ⁿ (aged 40-85 years), mean age IG=65 (SD 10.4) years, CG=62.5 (SD 12.3) years, 75% fe- male, n=21	[Pedometer] 4 sessions of 30-minute exercise counsel- ing (steps per day goal set- ting), pedometer feedback for 10 weeks + usual care	Conventional pulmonary rehabilitation of exercise training, dietary interven- tion, and psychoeduca- tional modules over 9 weeks	PA: pedometer steps per day ^g ; function: chair stand, arm curl, 8-foot up-and-go, 2-minute step test; other: Beck Depres- sion Inventory	Significantly improved 8-foot up-and-go test and 2-minute step test for in- tervention group; no sig- nificant differences be- tween groups in steps per day
Frederix et al [33], 2015, Bel- gium	Cardiac conditions (CAD ^o and CHF ^p), mean age 61 (SD 8.5) years, 17% female, n=140	[Multicomponent] 24-week PA telerehabilitation; exer- cise training protocols + center-based cardiac rehabil- itation for 12 weeks (usual care)	Center-based cardiac re- habilitation for 12 weeks (45 sessions—2 exercise sessions per week, di- etary consultation, and psychologist session)	PA: CPET ^q VO ₂ ^r peak ^g , accelerometer PA, self- report IPAQ converted to MET ^s -minutes per week of MVPA; quality of life:	Significant improvement in mean VO ₂ peak (<i>P</i> <.001), steps per day, MET-minutes per week of MVPA (<i>P</i> =.01), and health-related QoL ^t
					(<i>P</i> =.01) for intervention group



D'Amore et al

Study and country	Population, sample size (n)	Intervention ^a	Usual care	Outcomes	Key findings
Hansen et al [28], 2000, Denmark	COPD (no participa- tion in pulmonary re- habilitation in the pre- ceding 6 months), mean age 68.3 (SD 9.0) years, 55% fe- male, n=134	[Telerehabilitation] 10-week telerehabilitation program including group-based super- vised, standardized 35- minute exercise program via videoconference, followed by 20 minutes of patient ed- ucation 3 times per week	10-week conventional pulmonary rehabilitation program including group- based supervised, stan- dardized 60-minute exer- cise program 2 times per week in conjunction with 1 time per week educa- tion session lasting 60-90 minutes	PA: accelerometer PA; function: 6MWT ^{g,u} , 30- second sit-to-stand; qual- ity of life: HADS ^V , EQ- 5D ^{w;} COPD: COPD as- sessment test and Clini- cal COPD Questionnaire	No significant differ- ences in 6MWT; howev- er, intervention group maintained improvement at 22 weeks; significantly improved HADS and de- pression scores (P <.05) and COPD Assessment Test scores (P =.04) in in- tervention group

^aThe authors grouped interventions by the type of smart technology; groupings are indicated in square brackets at the beginning of each intervention description.

^bT2DM: type 2 diabetes mellitus.

^cIG: intervention group.

^dCG: control group.

^ePA: physical activity.

^fIPAQ: International Physical Activity Questionnaire.

^gPrimary outcomes of the individual studies.

^hMVPA: moderate to vigorous physical activity.

ⁱFITT: Frequency, intensity, type, and time

^jCABS: coronary artery bypass surgery.

^kMOS SF-36: Medical Outcomes Study 36-item Short Form survey.

^lTKR: total knee replacement.

^mPT: physiotherapy.

ⁿCOPD: chronic obstructive pulmonary disease.

^oCAD: coronary artery disease.

^pCHF: congestive heart failure

^qCPET: cardiopulmonary exercise testing.

^rVO₂: maximal oxygen uptake.

^sMET: metabolic equivalent.

^tQoL: quality of life.

^u6MWT: 6-minute walk test.

^vHADS: Hospital Anxiety and Depression Scale.

^wEQ-5D: EuroQoL 5 Dimensions.



D'Amore et al

Table 2. Characteristics of included studies with author names beginning with K to Z.

		e	e		
Study and country	Population, sample size (n)	Intervention ^a	Usual care	Outcomes	Key findings
Kawagoshi et al [29], 2015, Fin- land	COPD, mean age IG=74 (SD 8) years; CG=75 (SD 9) years, 11% female, n=39	[Pedometer] Pedometer + home-based pulmonary reha- bilitation including breath- ing retraining, exercise training, respiratory training, and monthly 45-minute edu- cation sessions	Home-based pulmonary rehabilitation including breathing retraining, exer- cise training, respiratory muscle training, and monthly 45-minute educa- tion sessions	PA: total PA as measured by accelerometer; func- tion: quadriceps muscle force; 6MWT; Pul- monary: Chronic Respira- tory Disease Question- naire	Significant increase in walking time (P =.04), dyspnea, and quadriceps force in intervention group; significant im- provements in pulmonary function tests, 6-minute walk distance, and Chronic Respiratory Dis- ease Questionnaire in both groups
King et al [42], 2020, United States	Community-dwelling adults aged 50 years, mean age 62.3 (SD 8.4) years, 78.8% fe- male, n=245	[Telerehabilitation] 1:1 ini- tial counseling session, pe- dometer use; additional (up to 28) 10 to 15 minutes counseling sessions by a virtual advisor over 12 months	1:1 initial counseling session, pedometer use; additional (up to 28) 10 to 15 minutes counseling sessions conducted by a human advisor over 12 months	PA: walking minutes per week ^b total PA, MVPA, daily PA measured by accelerometer, self-report weekly sedentary behav- ior; quality of life: Vitali- ty Plus scale	Significantly increased steps per day $(P=.02)$ in intervention group; signif- icant decreases in both groups for reported sedentary time
Kwan et al [41], 2020, Hong Kong	Mild cognitive impair- ment and physical frailty, mean age 71.0 (SD 9.0) years, 85% female, n=33	[Smartphone app] Smart- phone apps for individual- ized goals, to log PA data, performance reviews, and e- reminders; communication app for e-coaching, personal- ization of goal settings, and messages of praise + control intervention; all interven- tions were for 12 weeks	Conventional behavior change techniques via PA counseling, telephone follow-up, health educa- tion, and exercise train- ing. All interventions were for 12 weeks	PA: steps per day mea- sured by accelerometer; MVPA and non-MVPA per week measured by accelerometer; other: Fried frailty index; Mo- CA ^c	Significant increase in MVPA (P =.04), walking time (P =.03), steps per day (P =.02), brisk walking (P =.009), and peak cadence (P =.003) for intervention group; adherence to face-to-face sessions was 100% for both groups; smartphone compliance was 54.1 (SD 1.2) days per participant (range 0-56 days)
Maddison et al [34], 2015, New Zealand	Ischemic heart disease, mean age 60.2 (SD 9.3) years, 19% female, n=171	[Multicomponent] Automat- ed text messages for 24 weeks encouraging 30 min- utes per day MVPA 5 days per week + regular exercise prescription, behavior change strategies, website access with model vignettes, self-monitoring, information	Encouraged to participate in cardiac rehabilitation typically including educa- tion sessions, psychologi- cal support, and PA en- couragement and offer to join a supervised exercise club	PA: self-reported PA measured by IPAQ; oth- er: PVO_2^{d} assessed dur- ing $CPET^{b}$; self-efficacy and motivation to exer- cise; SF-36 and EQ-5D	No significant difference in PVO_2 between groups; significant improvements in self-report PA (P =.05), walking (P =.02), self-ef- ficacy (P =.04), and health-related QoL (P =.03) in intervention group
Mendoza et al [30], 2020, Chile	Stable COPD, mean age 68.7 (SD 8.5) years, 39.2% female, n=102	[Pedometer] Pedometer use and steps per day goals for 3 months, 3 monthly follow- up sessions with a physician and physiotherapist to in- crease step count	3 monthly counseling sessions with physician and PT to increase PA, advised to walk mini- mum 30 minutes per day	PA: steps per day ^b mea- sured by pedometer; oth- er: health status and exer- cise capacity	Significant increase in PA (P <.001) and exercise capacity (P =.03) in intervention group
Mouton and Cloes [45], 2015, Bel- gium	Community-dwelling adults (aged 50 years), mean age IG1=61.2 (SD 6.3) years; IG2=69.8 (SD 7.4) years; IG3=63.2 (SD 5.7) years; CG=66.1 (SD 6.8) years, 60% female, n=149	[Website] Three groups, all 3-month duration: (1) web- based intervention (PA pro- motion + monthly PA feed- back); (2) center-based inter- vention—12 weekly ses- sions of group exercise; and (3) mixed intervention (web- and center-based interven- tion)	No intervention received	PA: self-report using IPAQ-S ^e ; other: stages of change; awareness of PA; and participant accep- tance of intervention	Mixed intervention in- creased PA level (P =.04); center-based intervention (P <.001) and mixed inter- vention (P =.01) in- creased PA stages of change; web-based inter- vention (P =.02) and mixed intervention (P <.001) increased PA awareness



D'Amore et al

Study and country	Population, sample size (n)	Intervention ^a	Usual care	Outcomes	Key findings	
Roberts et al [35], 2019, United States	Community-dwelling adults (aged 60 years) with moderate to high risk of CVD ^f events, mean age 72 (SD 7.4) years, 60% female, n=40	[Wearable] Activity tracker + strategies to increase PA for 20 weeks; usual care (8- week center-based exercise intervention); goal to achieve 150 minutes of MVPA per week for 12 weeks; encouragement of nonexercise PA	Usual care including 2 for per week center-based exercise intervention for 8 weeks; instruction to achieve 150 minutes of MVPA per week for re- maining 12 weeks; behav- ioral counseling to en- courage nonexercise PA	PA: daily activity mea- sured by accelerometer; function: 6MWT; 4-me- ter gait speed; grip strength; SPPB ^g	Significant increase in steps per day for interven- tion group	
Tabak et al [31], 2014, Netherlands	Stable COPD, mean age IG=65.2 (SD 9.0) years; CG=67.9 (SD 5.7) years, 37% fe- male, n=34	[Multicomponent] 4-week daily use of mobile activity coach for feedback, motiva- tion, and target PA levels + usual care (medication and PT—weekly group training sessions)	Could consist of medica- tion and weekly group training PT sessions	PA: steps per day ^b mea- sured by pedometer; COPD: Clinical COPD Questionnaire (health status); other: compliance	No significant differ- ences in steps per day; nonsignificant improve- ment in health status in intervention group; 86% adhered to the activity coach	
Talbot et al [39], 2003, United States	Symptomatic knee OA ^h , aged \geq 60 years, mean age IG=69.6 (SD 6.7) years; CG=70.8 (SD 4.7) years, 76.5% female, n=34	[Pedometer] Pedometer use + daily step goals; education booklet on exercise and managing pain; usual care (12 sessions of 1-hour arthritis self-management education)	12 sessions of 1-hour arthritis self-management education (including a session on exercise)	PA: steps per day ^b by pedometer, PA over time (accelerometer); func- tion: leg muscle strength; 100-foot timed walk- turn-walk; timed stair climb; timed chair rise	23% steps per day in- crease for intervention group vs 15% decrease in control group; im- proved usual pace gait speed (<i>P</i> =.04) and isomet- ric leg strength (21%—compared with 3.5% loss in control group)	
Weinstock et al [37], 2011, United States	Diabetes mellitus, mean age 70.9 (SD 6.8) years, 63% fe- male, n=1650	[Multicomponent] Educa- tional videoconferencing for 4-6 weeks to review blood glucose and blood pressure measurements; pedometer use with goals set for 2 years	Usual care from PCP ⁱ ; PA encouraged by pe- dometer use with goals set between participant and PCP for 2 years	PA: diabetes self-care activities for assessment of PA; other: feasibility; acceptability; and CARE Depression Instrument	Significantly slower rate of decline in PA (P =.01) and lower rate of PI ^j (0.04); significantly higher PA levels (P <.001) in intervention group	
Yates et al [40], 2009, United King- dom	Overweight or obese (BMI ≥25), mean age 65 (SD 8) years, 34% female, n=87	[Pedometer] Pedometer use + 180-minute education ses- sion on causes and complica- tions of impaired glucose tolerance + exercise informa- tion	Two groups: (1) Same education session as inter- vention but no pedometer and (2) usual care—infor- mation pamphlet	PA: steps per day mea- sured by pedometer, self- reported walking by IPAQ, and total MVPA	Compared with usual care group 2, significant increases in steps per day, self-reported walking, and total MVPA at 3, 6, and 12 months in intervention group (all P <.05)	

^aThe authors grouped interventions by the type of smart technology; groupings are indicated in square brackets at the beginning of each intervention description.

^bPrimary outcomes of the individual studies.

^cMoCA: Montreal Cognitive Assessment.

^dPVO₂: peak oxygen uptake.

^eIPAQ-S: International Physical Activity Questionnaire-Short.

^fCVD: cardiovascular disease.

^gSPPB: Short Performance Physical Battery.

^hOA: osteoarthritis.

ⁱPCP: primary care provider.

^jPI: physical impairment.

Interventions

XSL•FO RenderX

Detailed descriptions of the smart technology interventions in each study are provided in Multimedia Appendix 1. A total of 16 studies included a single smart technology component, including smartphone apps [36,41], wearable activity trackers

https://www.jmir.org/2022/10/e36134

(eg, Fitbit) [35,38], telerehabilitation (eg, video conferencing, virtual advisor, or health buddy device) [28,32,42], and pedometers (ie, only provides step counts) [27,29,30,39,40,43,44], whereas the remaining 3 had multiple components, including video conference and pedometer [37]; website and SMS text messaging [34]; and website plus

pedometer, SMS text messaging, and email [33]. A total of 15 studies included smart technology and a face-to-face component in the intervention group [27,29-36,38-41,43,44]. Furthermore, 4 studies evaluated smart technology alone versus face-to-face alone [28,37,42,45]. The length of interventions ranged from 10 weeks [27] to 1 year [29], and follow-ups ranged from 6 weeks [32] to 2 years [37].

Risk of Bias

Overall, the risk of bias was a concern for studies included in this review. On the basis of the outcome with the highest risk of bias (ie, if we assessed risk of bias for 3 outcomes in a study and 1 of those was rated a high risk of bias and the other 2 were some concerns, we rated the study as high risk of bias), 14 to be high studies were judged risk [27,29,31,32,34,36,37,39-45], 4 studies had some concerns [28,30,35,38], and 1 study had a low risk of bias [33]. The areas of greatest concerns were missing outcome data (10/19, 53% high risk) and risk of bias related to measurement of the outcome (eg, awareness of intervention and influence of knowledge of intervention on the assessment; 9/19, 47% high risk). A summary figure is available in Multimedia Appendix 1.

Physical Activity

Overview

All included studies assessed the effect of smart technology interventions on PA [27-45]. The types of PA evaluated included steps per day [27,28,30,33,35,36,38-40,42], total PA [28,33,34,36,37,41-43,45], moderate to vigorous PA [32,38,40-42,44], and walking [29,33,34,40-42], assessed either

directly (eg, with pedometer or activity tracker) or indirectly (eg, self-report measures such as the International Physical Activity Questionnaire [33,34,36,40,45], Diabetes Self-Care Activities for assessment of PA [37], Community Health Activities Model Program for Seniors PA [42], Physical Activity Scale for the Elderly [41], activity diary [32], and Active Australia Survey [43]). Studies were grouped by type of PA, and 4 meta-analyses were performed for daily step counts, total PA, moderate to vigorous PA, and walking (Figure 2).

Compared with face-to-face interventions, interventions that included smart technology improved step count, with the meta-analysis of 11 studies and 738 participants demonstrating a MD of 1440 steps (95% CI 500-2390; Figure 2) [27,28,30,31,35,36,38-42]. Smart technology also improved total PA scores (8 studies, n=2069; SMD 0.17, 95% CI 0.17-0.52) and walking (4 studies, n=560; SMD 0.26, 95% CI 0.10-0.43) compared with face-to-face interventions. The meta-analysis of 3 studies (n=475) for moderate to vigorous PA was not statistically significant (SMD 0.04, 95% CI -0.14 to 0.22). We performed sensitivity analyses for all outcomes except moderate to vigorous PA. On the basis of the results of the risk of bias for the sensitivity analyses, we removed 5 studies with high risk of bias in the steps per day; however, the remaining 6 studies still favored smart technology with a MD of 2.03 (95% CI 0.35-3.71). Only 2 studies remained with 1388 participants for total PA; the difference was no longer significant with a SMD of 0.27 (95% CI -0.18 to 0.72). Finally, our sensitivity analysis for walking containing 2 studies (n=384) was not significant with a SMD of 0.22 (95% CI -0.04 to 0.48).

Figure 2. Meta-analysis of effect of smart technology versus face-to-face alone on physical activity (PA).

(A) Steps per day

study or Subgroup	Mean SD	Total Mean	-to-face SD To	otal Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
.1.1 Steps per day (direct measure)	10.714 1.75	04 0.45	4 7 7 1	01 0.00	2.25 /0.01.2.50	
hristiansen et al [38]. 2020	5.739 2.665	17 3.941	9.731	91 9.8% 19 9.3%	2.25 [0.91, 3.59]	
Blok et al [27], 2006	3.927 2.616	8 3.554	2.019	8 7.1%	0.37 [-1.92, 2.66]	
van et al [41], 2020	16.89091 5.13759	16 11.86525	5.78652	17 4.2%	5.03 [1.30, 8.75]	
endoza et al [30], 2020	7.088 2.253	50 4.0943	2.723	47 10.7%	2.99 [2.00, 3.99]	
berts et al [35], 2019	5 1.775	17 2.5	1.25	19 10.7%	2.50 [1.49, 3.51]	
bak et al [31], 2014	5.603 0.964 4.337 2.903	13 4.617	2 563	10 11.5%	0.99 [0.31, 1.66]	
tes et al [40], 2009	7.639 2.402	29 7.109	4.424	25 8.1%	0.53 [-1.41, 2.47]	
btotal (95% CI)		261	2	259 79.8%	1.76 [1.00, 2.53]	•
terogeneity: $Tau^2 = 0.75$; $Chi^2 = 21$. st for overall effect: $Z = 4.53$ (P < 0.0	57, df = 8 (P = 0.006) 00001)	; I ² = 63%				
1.2 Steps per day (direct measure) -	- interventions with	only Smart techn	ology			
ansen et al [28], 2020	2.379 1.966	67 3.306	2.335	67 11.4%	-0.93 [-1.66, -0.20]	
ng et al [42], 2020	7.211 4.272	44 5.55	3.4771	40 8.9%	1.66 [0.00, 3.32]	
eterogeneity: $Tau^2 = 2.92$; $Chi^2 = 7.82$	2, df = 1 (P = 0.005);	$l^2 = 87\%$		107 20.2%	0.20 [-2.27, 2.70]	
otal (95% CI)	54/	372	,	366 100.0%	1.44 [0.50, 2.39]	-
eterogeneity: Tau ² = 1.91: Chi ² = 60.4	47, df = 10 (P < 0.000	$(01); l^2 = 83\%$		200 1000/0	2111 [0120] 2122]	
est for overall effect: Z = 2.99 (P = 0.0	003)					-4 -2 0 2 4 Face-to-face alone. Smart technology include
est for subgroup differences: $Chi^2 = 1$.25, df = 1 (P = 0.26)	$I^2 = 20.2\%$				Face-to-race alone Smart technology include
B) Total PA						
2) 1000111	Smart technology	Face-to	o-face	Std	. Mean Difference	Std. Mean Difference
udy or Subgroup 2.1 Total physical activity (self-re	Mean SD T eported)	otal Mean	SD Total	Weight I	V, Random, 95% CI	IV, Random, 95% CI
onso-Dominguez et al [36], 2019	2,939 2,785	94 2,070 1,	946 91	15.0%	0.36 [0.07, 0.65]	
rmit et al [43], 2005	241 28	11 259	127 8	2.6%	-0.20 [-1.12, 0.71]	· · · · · · · · · · · · · · · · · · ·
ederix et al [33], 2015	2,077 2,357	69 1,075 1,	203 70	12.6%	0.53 [0.20, 0.87]	
wan et al [41], 2020	88.41 27.09	16 76.01	31.4 17	4.3%	0.41 [-0.28, 1.10]	
addison et al [34], 2015 ubtotal (95% CI)	1,555 1,220	58 1,321.1 1, 248	285 68	12.1%	0.19 [-0.17, 0.54]	
eterogeneity: Tau ² = 0.00; Chi ² = 3.	.42, df = 4 (P = 0.49)	$I^2 = 0\%$	2.94	1017/0	5133 [0127, 0132]	
2.2 Total physical existing $f = 1$	unorted)	and with such a		lam		
ing et al [42], 2020	502.2 875	123 433.4	803 122	17.4%	0.08 [-0.17 0 33]	
outon and Cloes [45], 2015	1,309.3 766.9	33 1,513.2 8	67.7 40	8.3%	-0.24 [-0.71, 0.22]	
einstock et al [37], 2011	2.79 2.31	616 2.63	2.32 633	27.7%	0.07 [-0.04, 0.18]	+
ubtotal (95% CI)		772	795	53.3%	0.06 [-0.04, 0.16]	*
					0100 [010 1] 0120]	•
leterogeneity: $Tau^2 = 0.00$; $Chi^2 = 1$.	.72, df = 2 (P = 0.42) 0.26)	$I^2 = 0\%$			0100 (010 1, 0120)	-
leterogeneity: $Tau^2 = 0.00$; $Chi^2 = 1$. lest for overall effect: $Z = 1.12$ (P = 0 local (95% CI)	.72, df = 2 (P = 0.42) 0.26)	020	1049	100.0%	0.17 (0.02 0.33)	
Meterogeneity: $Tau^2 = 0.00$; $Chi^2 = 1$. Test for overall effect: $Z = 1.12$ (P = 0 Total (95% CI) Meterogeneity: $Tau^2 = 0.02$; $Chi^2 = 1$.72, df = 2 (P = 0.42) 0.26) 1 2 91 df = 7 (P = 0.0)	$1^2 = 0\%$ 020 7): $1^2 = 4.6\%$	1049	100.0%	0.17 [0.02, 0.32]	•
Heterogeneity: Tau ² = 0.00; Chi ² = 1. Fest for overall effect: Z = 1.12 (P = 0 Fotal (95% Cl) Heterogeneity: Tau ² = 0.02; Chi ² = 12 Fest for overall effect: Z = 2.15 (P = 0	.72, df = 2 (P = 0.42) 0.26) 1 2.91, df = 7 (P = 0.05 0.03)	020 7); 1 ² = 46%	1049	100.0%	0.17 [0.02, 0.32]	-1 -0.5 0 0.5 Face-to-face alone Smart technology include
teterogeneity: Tau ² = 0.00; Chi ² = 1. 'est for overall effect: $Z = 1.12$ (P = 0 Total (95% CI) teterogeneity: Tau ² = 0.02; Chi ² = 11 'est for overall effect: $Z = 2.15$ (P = 0 'est for subgroup differences: Chi ² =	.72, df = 2 (P = 0.42) 0.26) 1 2.91, df = 7 (P = 0.02) 0.03) 7.77, df = 1 (P = 0.02)	020 7); $l^2 = 46\%$ 005), $l^2 = 87.1\%$	1049	100.0%	0.17 [0.02, 0.32]	-1 -0.5 0 0.5 Face-to-face alone Smart technology include
teterogeneity: Tau ² = 0.00 ; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02 ; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 est for subgroup differences: Chi ² = (C) Moderate to via	$\begin{array}{l}$	020 7); 1 ² = 46% 005), 1 ² = 87.1%	1049	100.0%	0.17 [0.02, 0.32]	-1 -0.5 0 0.5 Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = C otal (95% Cl) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C est for subgroup differences: Chi ² = (C) Moderate to vi Smart Mean	$\begin{array}{c} & ,72,df=2\;(P=0,42)\\ & & 1\\ 2.91,df=7\;(P=0.02)\\ 0.03)\\ & 7.77,df=1\;(P=0.02)\\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$	$1; 1^2 = 0\%$ 020 7); 1^2 = 46% 005), 1^2 = 87.1% Face-to-face Mean Si	1049 e D <u>Total W</u>	100.0% Std. N Veight IV,	0.17 [0.02, 0.32] tean Difference Random, 95% CI	-1 -0.5 0 0.5 1 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% Cl) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = 0 est for subgroup differences: Chi ² = (C) Moderate to vigorous PA (seel tudy or Subgroup Mean 3.11 Moderate to vigorous PA (seel Mean PA (2009)	72, df = 2 (P = 0.42) 0.26) 1 2.91, df = 7 (P = 0.0) 0.03) 7.77, df = 1 (P = 0.0) gorous PA t technology 5D Total f-reported	$i; 1^2 = 0\%$ 020 $7); 1^2 = 46\%$ $005), 1^2 = 87.1\%$ Face-to-face Mean Si	1049 e D Total W	100.0% Std. N Veight IV,	0.17 [0.02, 0.32] tean Difference Random, 95% CI	-1 -0.5 0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% Cl
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% Cl) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = 0 est for subgroup differences: Chi ² = (C) Moderate to vigorous PA (sell ates et al [40], 2009 1,589 1 ates et al [40], 2030 1,589 1 (C) 1.580 1	$\begin{array}{c} & 7.2, df = 2 \ (P = 0.42) \\ 0.26) \\ & 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \hline \\ \textbf{gorous PA} \\ \textbf{t technology} \\ \hline \\ \textbf{f-reported} \\ 2.412.24 \\ 27 \ 1, \\ 118 \\ 8 \\ 9 \end{array}$	(; l ² = 0%) 020 7); l ² = 46% 005), l ² = 87.1% Face-to-face Mean Si 452.33 1,773.1 126.9 105	1049 e D Total W 5 23 7 99	100.0% Std. N Veight IV, 10.5% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI	Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% Cl
terogeneity: Tau ² = 0.00; Chi ² = 1. test for overall effect: $Z = 1.12$ (P = 0 obtal (95% CI) terogeneity: Tau ² = 0.02; Chi ² = 12 terogeneity: Tau ² = 0.02; Chi ² = 12 terogeneity: Tau ² = 0.02; Chi ² = 12 test for subgroup differences: Chi ² = C) Moderate to vigorous Pa (sell udy or Subgroup Moderate to vigorous Pa (sell test et al (40), 2009 1,558 3 trnason et al (32), 2009 145.4 152 4 152	.72, df = 2 (P = 0.42) 0.26) 1 2.91, df = 7 (P = 0.0) 0.03) 7.77, df = 1 (P = 0.0) gorous PA t technology SD Total f-reported 2.412.24 27 1, 118.8 81 179.7 123	(; l ² = 0%) 020 7; l ² = 46% 005), l ² = 87.1% Face-to-face 452.33 1,773.1 126.9 195. 105.4 155.	1049 e D Total W 5 23 7 99 5 122	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 37.7% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.24]	Face-to-face alone Smart technology include
terogeneity: Tau ² = 0.00; Chi ² = 1. set for overall effect: $Z = 1.12$ (P = 0 obtal (95% CI) tetrogeneity: Tau ² = 0.02; Chi ² = 11 set for overall effect: $Z = 2.15$ (P = 0 c) Moderate to vigorous PA (seel tudy or Subgroup Mean 3.1 Moderate to vigorous PA (seel tets et al [40], 2009 1.589 transan et al [32], 2009 145.4 ng et al [42], 2020 103.4 bitotal (95% CI)	$\begin{array}{c} & ,72, df = 2 \ (P = 0.42) \\ & 0.26) \\ & 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \hline \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \hline \textbf{SD Total} \\ \hline \textbf{f-reported} \\ 2,412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \end{array}$	i; l² = 0% 020 7; l² = 46% 005), l² = 87.1% Face-to-facc Mean 126.9 126.4 153. 105.4 153.	e D Total W 5 23 7 99 5 122 244 10	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 51.8% -0 00.0%	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22]	Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Ch ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = 0 C) Moderate to vigorous PA (self) (C) Moderate to vigorous PA (self) tudy or Subgroup Mean 3.1 Moderate to vigorous PA (self) ates et al [40], 2009 1.589 J mrason et al [32], 2009 145.4 ing et al [42], 2020 103.4 eterogeneity: Tau ² = 0.00; Chi ² = 0 eterogeneity: Tau ² = 0.00; Chi ² = 0	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 179.7 \ 123 \\ \textbf{sol} \\ s$	i; l ² = 0% 020 7; l ² = 46% 005), l ² = 87.1% Face-to-facc Mean Si 452.33 1,773.1 126.9 195. 105.4 153. 2); l ² = 0% 2%	1049 e D Total W 5 23 7 99 5 122 244 10	100.0% Std. M Veight IV, 10.5% 0 37.7% 0 51.8% -0 00.0% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22]	Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = C otal (95% Cl) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = C C) Moderate to zero chi ² = (C) Moderate to vigorous PA (seel tudy or Subgroup differences: Chi ² = Moderate to vigorous PA (seel tates et al [40], 2009 145.4 arnason et al [32], 2009 145.4 ing et al [42], 2020 103.4 eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect Z = 0.46 (P = col 205% Ch)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PAA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2,412,24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \end{array}$	$\begin{aligned} & \mathbf{r}; \ \mathbf{r}^2 = 0\% \\ & 020 \\ & 7; \ \mathbf{r}^2 = 46\% \\ & 005; \ \mathbf{r}^2 = 87.1\% \\ & \mathbf{Face-to-facc} \\ & \mathbf{Mean} \mathbf{Si} \\ & 452.33 1,773.1 \\ & 126.9 195. \\ & 105.4 153. \\ & 2; \ \mathbf{r}^2 = 0\% \end{aligned}$	1049 e D Total W 5 23 7 99 5 122 244 10 244 10	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 51.8% -0 00.0% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .006 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22]	Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Ch ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vig (C) Moderate to vig Smart tudy or Subgroup Mean .3.1 Moderate to vigorous PA (sel tates et al [40], 2009 1,589 .1589 CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{sD Total} \\ \hline \textbf{f-reported} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \\ \hline \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{231} \hline \textbf{231} \\ \hline \textbf{231}$	$; l^2 = 0\%$ 020 $7; l^2 = 46\%$ 1005) , $ l^2 = 87.1\%$ Face-to-fact Mean Si 452.33 1,773.1 126.9 195. 105.4 153. 2) ; $ l^2 = 0\%$	1049 e D Total W 5 23 7 99 5 122 244 10 244 10	100.0% Std. N Veight IV. 10.5% 0 51.8% -0 000.0% 0 000.0% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22]	Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI
teterogeneity: Tau ² = 0.00; Chi ² = 1, est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 cst for subgroup differences: Chi ² = (C) Moderate to vigorous PA (self tudy or Subgroup Mean .3.1 Moderate to vigorous PA (self ates et al [40], 2009 11,589 arrason et al [32], 2009 145,4 ing et al [42], 2020 103,4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PAA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 2.7 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65 \\ 0.65 \\ \textbf{0.65} \end{array}$	$\begin{array}{l} & (1) \\ & (2) \\$	1049 D Total W 5 23 7 99 5 122 244 10 244 10	100.0% Std. N Veight IV, 10.5% 0 51.8% -0 00.0% 0 00.0% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22]	-0.5 Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = C C) Moderate to Z = 2.15 (P = C C) Moderate to Vigorous PA (seel tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous PA (seel tates et al (40), 2009 1,589 arnason et al [32], 2009 145.4 ing et al [42], 2020 103.4 ates et al [40], 2009 145.4 ing et al [42], 2020 103.4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup differences: Not ap	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PAA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 1, 12, 12, 24 \\ 2, 412, 24 \\ 2, 412, 24 \\ 2, 11, 18, 8 \\ 179, 7 \\ 123 \\ 179, 7 \\ 123 \\ 123 \\ 1, 40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{pplicable} \end{array}$	$\begin{aligned} & (r) = 0\% \\ \hline 020 \\ \hline 07; & (r^2 = 46\% \\ \hline 005), & (r^2 = 87.1\% \\ \hline Face-to-fac \\ \hline Mean & Si \\ \hline 452.33 & 1,773.1 \\ \hline 126.9 & 195. \\ \hline 105.4 & 153. \\ \hline 105.4 & 153. \\ \hline 2); & (r^2 = 0\% \\ \hline 2); & (r^2 = 0\% \\ \hline \end{aligned}$	1049 D Total W 5 23 7 99 5 122 244 10 244 10	100.0% <u>Veight</u> IV, 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22]	Std. Mean Difference IV, Random, 95% CI
leterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C 'otal (95% C)) leterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C (C) Moderate to Z = 2.15 (P = C (C) Moderate to Vigorous PA (sell tudy or Subgroup differences: Chi ² = (C) Moderate to Vigorous PA (sell tates et al (40), 2009 1.589 2 arnason et al (32), 2009 145.4 ling et al (42), 2020 103.4 untotal (95% C)) leterogeneity: Tau ² = 0.00; Chi ² = 0 otal (95% C) leterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for overall effect: Z = 0.46 (P = est for subgroup differences: Not ap (D) Walking	7.2, df = 2 (P = 0.42) 0.26) 1 2.91, df = 7 (P = 0.0) 0.03) 7.77, df = 1 (P = 0.0) gorous PA technology 50 Total f-reported) 2.412.24 27 1, 118.8 81 179.7 123 231 0.40, df = 2 (P = 0.82) 0.65) pplicable	$F_{acc-10-fac} = 0\%$ $F_{acc-10-fac} = 10\%$	1049 D Total W 5 23 7 99 5 122 244 10 244 10	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 Std. Mo	0.17 [0.02, 0.32] tean Difference Random, 95% Ct 106 [-0.49, 0.62] 11 [-0.18, 0.41] 104 [-0.14, 0.22] 04 [-0.14, 0.22] an Difference	Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1, est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous Chi ² = (C) Moderate to vigorous PA (seef tudy or Subgroup Mean 3.11 Moderate to vigorous PA (seef tates et al [40], 2009 11,589 arrason et al [32], 2009 145.4 ing et al [42], 2020 103.4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for overall effect: Z = 0.46 (P = est for subgroup differences: Not ap (D) Walking	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 271 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{SD Total} \\ \end{array}$	$ _{1}^{2} = 0\%$ 020 $7 _{1}^{2} = 46\%$ 1005), $ ^{2} = 87.1\%$ Face-to-face Mean SI 126.9 195. 105.4 153. 127.1 126.9 195. 105.4 153. 107.1 127.1	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 e Total Wei	100.0% Std. N Veight IV, 10.5% 0 51.8% -0 00.0% 0 00.0% 0 Std. Me std. Me	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22]	Std. Mean Difference IV, Random, 95% CI Galage State Allower State All
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous Chi ² = (C) Moderate to vigorous PA (seli tudy or Subgroup Mean 3.1 Moderate to vigorous PA (seli tates et al (40], 2009 1,589 1 marsanot et al (32), 2009 1,589 1 marsanot et al (32), 2009 1,589 1 marsanot et al (32), 2009 1,589 1 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup differences: Not al (D) Walking Mean 4.1 Walking (self-reported)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.6) \\ \hline \textbf{gorous PA} \\ t \ technology \\ \hline \textbf{sD Total} \\ \hline \textbf{f-reported} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \hline \textbf{gorous PA} \\ \hline \textbf{sD Total} \\ \hline \textbf{sD Total} \\ \hline \textbf{rt technology} \\ \hline \textbf{sD Total} \\ \hline \ \ \textbf{sD Total} \\ \hline \ sD T$	$\begin{array}{r} \text{(i)} i; i^2 = 0\% \\ \hline \textbf{020} \\ \hline \textbf{77}; i^2 = 46\% \\ \hline \textbf{005}, i^2 = 87.1\% \\ \hline \textbf{Face-to-face} \\ \hline \textbf{452.33} & 1,773.1 \\ \hline \textbf{126.9} & 195. \\ \hline \textbf{105.4} & 153. \\ \hline \textbf{126.9} & 195. \\ \hline \textbf{105.4} & 153. \\ \hline \textbf{27}; i^2 = 0\% \\ \hline \textbf{Face-to-face} \\ \hline \textbf{Mean} & \textbf{5D} \end{array}$	1049 <u>D Total W</u> 5 23 7 99 5 122 244 10 244 10 244 10 e Total Wei	100.0% Std. N Veight IV, 10.5% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 Std. Me ight IV, R	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] an Difference andom, 95% CI	Std. Mean Difference IV, Random, 95% CI
terogeneity: Tau ² = 0.00; Chi ² = 1. sst for overall effect: Z = 1.12 (P = 0 obtal (95% CI) terogeneity: Tau ² = 0.02; Chi ² = 12 sst for overall effect: Z = 2.15 (P = 0 C) Moderate to Vigorous Par (Sell udy or Subgroup differences: Chi ² = C) Moderate to vigorous PA (Sell udy or Subgroup Mean 3.1 Moderate to vigorous PA (Sell utes et al (40), 2009 1.45,4 ng et al (42), 2009 1.45,4 ng et al (42), 2009 1.45,4 ng et al (42), 2009 1.45,4 uterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = total (95% CI) teterogeneity: Tau ² = 0.00; Chi ² = 0 test for overall effect: Z = 0.46 (P = total (95% CI) teterogeneity: Tau ² = 0.00; Chi ² = 0 test for overall effect: Z = 0.46 (P = dotal (95% CI) teterogeneity: Tau ² = 0.00; Chi ² = 0 test for overall effect: Z = 0.46 (P = dotal (95% CI) teterogeneity: Tau ² = 0.00; Chi ² = 0 test for overall effect: Z = 0.46 (P = dotal (95% CI) teterogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = dotal (95% CI) tetrogeneity: Tau ² = 0.00; Chi ² = 0 St for overall effect: Z = 0.46 (P = St for overall effect: Z = 0.46 (P = St for overall effect: Z = 0.4	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{sD Total} \\ \textbf{sD Total} \\ \textbf{967 \ 69} \end{array}$	$Face-to-facMean SD Face-to-fac Mean SD Face-to-fac Mean SD Face-to-fac Mean SD 452.33 1,773.1 126.9 195. 105.4 153. 2); l^2 = 0\%$	1049 <u>D Total W</u> 5 23 7 99 5 122 244 10 244 10 <u>244 10</u> e <u>Total Wei</u> 70 24	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 Std. Me ight IV, R: 4.7% 0.	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] an Difference andom, 95% CI .38 [0.04, 0.72]	Std. Mean Difference IV, Random, 95% CI Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = 0 C) Moderate to vigorous P(1) (C) M	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 2.7 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ gorous Pair Pair Pair Pair Pair Pair Pair Pair$	$\begin{array}{c} \text{$\mathbf{P}_{1}: 1^{2} = 0\%$}\\ \hline \textbf{020}\\ \hline \textbf{020}\\ \hline \textbf{7}: 1^{2} = 46\%\\ \hline \textbf{1005}, 1^{2} = 87.1\%\\ \hline \textbf{Face-to-facc}\\ \hline \textbf{Mean} & \textbf{SI}\\ \hline \textbf{126.9} & 195.\\ \hline \textbf{105.4} & 153.\\ \hline \textbf{127.1}^{2} = 0\%\\ \hline \textbf{Face-to-facc}\\ \hline \textbf{Mean} & \textbf{SD}\\ \hline \textbf{491} & \textbf{583}\\ \hline \textbf{360.9} & \textbf{374} \end{array}$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 70 24 68 22	Std. N Veight IV. 10.5% 0 37.7% 0 00.0% 0 00.0% 0 00.0% 0 Std. Me ight IV. R: 4.7% 2.3% 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22]	-0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI -0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1. est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous PA (sel tudy or Subgroup Mean 3.1 Moderate to vigorous PA (sel tates et al [40], 2009 15.84 marsson et al [32], 2009 145.4 ing et al [42], 2020 103.4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.05; Chi ² = 0 est for overall effect: Z = 0.46 (P = st for subgroup Mean 4.1 Walking (self-reported) rederix et al [33], 2015 766 addison et al [34], 2005 512.3 tates et al [40], 2009 2,292	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 2.31 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{sD Total} \\ \textbf{rotal} \\ \textbf{sD Total} \\ \textbf{rotal} \\ \textbf{sD Total} \\ \textbf{sD Total } \\ \textbf{sD Total} \\ \textbf{sD Total } \\ sD$	$\begin{array}{r} {}_{(1)}: i^2 = 0\% \\ \hline {020} \\ 7; i^2 = 46\% \\ 1005), i^2 = 87.1\% \\ \hline \\ \hline \\ Face-to-face \\ 126.9 & 195. \\ 105.4 & 153. \\ 126.9 & 195. \\ 105.4 & 153. \\ 2); i^2 = 0\% \\ \hline \\ $	1049 <u>D Total W</u> 5 23 5 122 244 10 244 10 244 20 7 0 24 6 22 23 6 2 23 6	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 51.8% 000.0% 0 000.0% 0 0 0 0 0 0 0 0 0	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [0.01, 0.72] .36 [0.01, 0.71] .4 [-0.12, 1.01]	Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C C) Moderate to vigorous Pci (Sch tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous Pci (Sch tudy or Subgroup Mean 3.1 Moderate to vigorous Pci (Sch tates et al (40) (2009 145,4 ing et al (42), 2009 145,4 ing et al (42), 2009 145,4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CD) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CD) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup differences: Not aj (D) Walking (self-reported) Mean 4.1 Walking (self-reported) at (33), 2015 796 faddison et al (34), 2015 726 iaddison et al (34), 2015 726	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{sD Total} \\ for any for all for al$	Face-to-facMean SD Face-to-fac Mean SI $Face-to-fac Mean SI Face-to-fac Mean SI Face-to-fac Mean SD 452.33 1,773.1 126.9 195. 105.4 153. 2); I2 = 0% Face-to-fac Mean SD 491 583 360.9 374 1,585 1,389.5$	049 D Total W 5 23 7 99 5 122 244 10 244 10 10 244 10 244 10 245 20 23 8 161 55 23 8 161 55 244 10 244 10 245 10 245 10 245 10 245 10 245 10 245 10 245 10	100.0% Std. N Veight IV, 10.5% 0 51.8% -0 00.0% 0 00.0% 0 Std. Me ight IV, R: 4.7% 0, 2.3% 0, 8.8% 0,4 5.7% 0,	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.4]] .01 [-0.26, 0.24] .04 [-0.14, 0.22] an Difference andom, 95% CI .38 [0.04, 0.72] .36 [0.01, 0.71] .10] .04 [-0.1]	Std. Mean Difference IV, Random, 95% CI
teterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous Pci (Sec) tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous Pci (Sec) armason et al (32), 2009 145,4 ing et al (42), 2009 145,4 undstotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for subgroup Mean 4.1 Walking (self-reported) taddison et al (34), 2015 512, 3 as et al (40), 2009 2,292 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PAA} \\ \textbf{technology} \\ \textbf{back technology} \\ \textbf{constraints} \\$	$\begin{array}{r} {} (r^2 = 0\%) \\ \hline 020 \\ \hline 07; \ l^2 = 46\% \\ \hline 005), \ l^2 = 87.1\% \\ \hline Face-to-fac \\ \hline Mean \\ 126.9 \\ 105.4 \\ 153. \\ 105.4 \\ 153. \\ 2); \ l^2 = 0\% \\ \hline \hline \\ \hline \\ Face-to-fac \\ \hline Mean \\ SD \\ \hline \\ 491 \\ 583 \\ 360.9 \\ 374. \\ 1,585 \\ 1,389.5 \\ 97); \ l^2 = 0\% \end{array}$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 245 25 25 25 25 25 25 25 25 25 25	100.0% Std. N Veight IV, 10.5% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 Std. Me ight IV, R: 4.7% 0, 2.3% 0, 8.8% 0,4, 5.7% 0,	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .01 [-0.26, 0.24] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .05 [-1] .05 [-1] .05 [-1] .06 [-0.14, 0.22] .07 [-1] .07 [-1] .08 [-1] .08 [-1] .09 [-1] .09 [-1] .09 [-1] .01 [-1] .01 [-1] .02 [-1] .03 [-1] .04 [-1] .04 [-1] .04 [-1] .04 [-1] .05	Std. Mean Difference IV, Random, 95% CI Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C (C) Moderate to vigorous Pci (Sec) tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous Pci (Sec) armason et al (32), 2009 145,4 ing et al (42), 2009 145,4 undotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% C) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup differences: Not aj (D) Walking (seff-reported) ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for subgroup differences: Not aj (A:1 Walking (seff-reported) ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 3.35 (P = est for overall effect: Z = 3.35 (P =	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{2412.24} \\ \textbf{27} \\ \textbf{118.8} \\ 179.7 \\ \textbf{123} \\ \textbf{231} \\ \textbf{0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{pplicable} \\ \hline \textbf{rt technology} \\ \textbf{5D Total} \\ \hline \textbf{967} \\ \textbf{69} \\ \textbf{467} \\ \textbf{58} \\ 1,698.28 \\ 27 \\ \textbf{154} \\ 0.066, df = 2 \ (P = 0.5) \\ \textbf{154} \\ 0.06, df = 2 \ (P = 0.5) \\ \textbf{154} \\ 0.06, df = 2 \ (P = 0.5) \\ \textbf{156} \\ \textbf{1698.28} \\ 27 \\ \textbf{154} \\ 0.06, df = 2 \ (P = 0.5) \\ \textbf{156} \\ \textbf{1698.28} \\$	Face-to-facMean SD 491 583 492 12 = 0% Face-to-fac Mean SD 492 12 = 0% Face-to-fac Mean SD 491 583 360.9 374 1,585 1,389.5 371; 12 = 0%	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 244 10 244 10 244 10 244 10 244 10 244 10 10 10 244 10 244 10 24	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 37.7% 0 00.0% 0 00.0% 0 Std. Me ight IV, R; 4,7% 0, 2.3% 0,4 8.8% 0,4	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .01 [-0.26, 0.24] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .05 [-1] .05 [-1] .05 [-1] .05 [-1] .06 [-1] .07	Std. Mean Difference IV, Random, 95% CI
leterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% C)) leterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = C est for subgroup differences: Chi ² = (C) Moderate to vigorous PA (seel) tudy or Subgroup means and the set of the se	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PAA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2,412,24 \ 27 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 179.7 \ 123 \\ 231 \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{gorous PAB} \\ gorous PA$	$\begin{array}{r} {}; \ l^2 = 0\% \\ \hline 020 \\ \hline 07; \ l^2 = 46\% \\ \hline 005), \ l^2 = 87.1\% \\ \hline Face-to-fac \\ \hline Mean SI \\ 126.9 \\ 195. \\ 105.4 \\ 153. \\ 127. \ l^2 = 0\% \\ \hline \\ 127. \ l^2 = 0\% \\ \hline \\ \hline \\ 1360.9 \\ 374 \\ 1.585 \\ 1.389.5 \\ 377; \ l^2 = 0\% \\ \hline \\ 1583 \\ 1.389.5 \\ 377; \ l^2 = 0\% \\ \hline \\ 1583 \\ 1.389.5 \\ 1.3$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 6 70 24 68 22 23 8 161 55 5 5 5 5 5 22 23 24 10 24 23 24 10 24 24 24 23 24 24 24 24 24 24 24 24 24 24	Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 8.8% 0.4 5.7% 0. 4.3% 0.3	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.16, 0.61] .1[-0.14, 0.36]	Std. Mean Difference IV, Random, 95% CI
teterogeneity: Tau ² = 0.00; Chi ² = 11 est for overall effect: Z = 1.12 (P = 0 otal (95% CI) etterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous PA (sel tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous PA (sel ates et al [40], 2009 145.4 ing et al [42], 2020 103.4 ubtotal (95% CI) etterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) (D) Walking (D) Walking (D) Walking (A1 Walking (self-reported) rederix et al [31], 2015 142, 3 ates et al [40], 2009 2,922 ubtotal (95% CI) etterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup Mean (A.1 Walking (self-reported) rederix et al [32], 2015 1512, 3 ates et al [40], 2005 2,922 ubtotal (95% CI) etterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 3.35 (P = est for overall effect: Z = 3.35 (P = ubtotal (95% CI)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 2.7 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ 2.31 \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82 \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{freenoty} \\ \textbf{sD Total} \\ \textbf{freenoted} \\ \textbf{gorous PA} \\ \textbf{starsec} $	$\begin{array}{r} {} ; l^2 = 0\% \\ \hline 020 \\ 7; l^2 = 46\% \\ 1005), l^2 = 87.1\% \\ \hline Face-to-face \\ Mean SI \\ 126.9 \\ 195. \\ 105.4 \\ 153. \\ 2); l^2 = 0\% \\ \hline Face-to-face \\ \hline Mean SD \\ 2); l^2 = 0\% \\ \hline Face-to-face \\ 360.9 \\ 374 \\ 1,585 \\ 1,389.5 \\ 97); l^2 = 0\% \\ \hline Hy Smart technol \\ 131.9 \\ 183.3 \\ \hline \end{array}$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 244 10 244 10 10 244 10 10 244 22 11 5 5 10 2 2 4 10 12 4 12 4 12 2 4 12 12 4 12 12 4 12 12 12 12 12 12 12 12 12 12	Std. N Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 000.0% 0 00.0% 0 00.0% 0 8.8% 0.4 5.7% 0. 4.3% 0.1 4.3% 0.1	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .01 [-0.26, 0.24] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [0.04, 0.72] .38 [0.16, 0.61] .11 [-0.14, 0.36] .12 [-0.14, 0.36] .12 [-0.14, 0.36]	Std. Mean Difference IV, Random, 95% CI -0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI -0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C (C) Moderate to vigorous Pci (Sec) tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous Pci (Sec) arnason et al (32), 2009 145,4 ling et al (42), 2009 145,4 uing et al (42), 2009 145,4 eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for overall effect: Z = 0.46 (P = est for subgroup differences: Not aj (D) Walking tudy or Subgroup Mean 4.1 Walking (self-reported) ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = est for overall effect: Z = 3.35 (P = 4.4.2 Walking (self-reported) - int ing et al (42), 2020 153,9 ubtotal (95% CI)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{2412.24} \\ \textbf{271}, \\ 118.8 \\ 179.7 \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{5D Total} \\ \textbf{753} \\ \textbf{1}, \textbf{698.28} \\ \textbf{271} \\ \textbf{154} \\ 0.065, df = 2 \ (P = 0.52) \\ 0.008) \\ \textbf{rt technology} \\ \textbf{154} \\ \textbf{156} \\ \textbf{156}$	$\begin{array}{r} {} (r^2 = 0\%) \\ \hline 020 \\ \hline 07); \ l^2 = 46\% \\ \hline 005), \ l^2 = 87.1\% \\ \hline Face-to-fac \\ \hline Mean & Sil \\ \hline 452.33 & 1,773.1 \\ \hline 126.9 & 195. \\ \hline 105.4 & 153. \\ \hline 20; \ l^2 = 0\% \\ \hline 21; \ l^2 = 0\% \\ \hline 22; \ l^2 = 0\% \\ \hline 491 & 583 \\ \hline 360.9 & 374 \\ \hline 1,585 & 1,389.5 \\ \hline 37); \ l^2 = 0\% \\ \hline 195.4 & 120.5 \\ \hline 105.4 & 1$	1049 p Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 68 22 23 8 161 55 5 5 161 55 5 5 5 5 5 5 22 2 4 4 122 44 122 44 122 44	100.0% Std. N Veight IV, 10.5% 0 37.7% 0 37.7% 0 00.0% 0 00.0% 0 00.0% 0 Std. Me ight IV, R; 4.7% 0, 8.8% 0,4 4.3% 0,1 4.3% 0,1	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .01 [-0.26, 0.24] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .038 [0.04, 0.72] .38 [0.01, 0.71] .38 [0.16, 0.61] .11 [-0.14, 0.36] .11 [-0.14, 0.36]	Std. Mean Difference IV, Random, 95% CI Std. Mean Difference IV, Random, 95% CI Std. Mean Difference IV, Random, 95% CI
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C C) Moderate to vigorous P(A) (C) (C) (Chi (C) (Chi ² = 0) est est est al (32), 2009 (Chi ² = 0) est for overall effect: Z = 0.46 (P = est for overall	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ 0.03) \\ 1.020 \\ \textbf{gorous PAA} \\ 1.123 \\ 1.179, 7 \\ 1.23 \\ 1.123 \\ 1.179, 7 \\ 1.23 \\ 1.123 \\ 1.179, 7 \\ 1.23 \\ 1.123 \\ 1.179, 7 \\ 1.23 \\ 1.1123 \\ 1.179, 7 \\ 1.23 \\ 1.231 \\ 1.1123 \\ 1.11$	$\begin{array}{r} {}; \ l^2 = 0\% \\ \hline 020 \\ 7; \ l^2 = 46\% \\ 1005), \ l^2 = 87.1\% \\ \hline Face-to-facc \\ Mean SI \\ 126.9 \\ 195. \\ 105.4 \\ 153. \\ 2); \ l^2 = 0\% \\ \hline Face-to-facc \\ Mean SD \\ 2); \ l^2 = 0\% \\ \hline 105.4 \\ 1585 \\ 1,389.5 \\ 360.9 \\ 374 \\ 1,585 \\ 1,389.5 \\ 377; \ l^2 = 0\% \\ \hline 105.4 \\ 1,585 \\ 1,389.5 \\ 377; \ l^2 = 0\% \\ \hline 105.4 \\ 1,585 \\ 1,389.5 \\ 1,389.5 \\ 377; \ l^2 = 0\% \\ \hline 105.4 \\ 1,585 \\ 1,389.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\ 1,399.5 \\$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 70 24 68 22 23 8 161 55 500gy 122 44	Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 8.8% 0.4 5.7% 0. 8.8% 0.4 5.7% 0. 4.3% 0.1	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .05 [0.01, 0.71] .05 [0.01, 0.71] .05 [0.01, 0.71] .06 [-0.14, 0.36] .07 [0.02, 0.32] .08 [0.04, 0.72] .09 [0.01, 0.71] .09 [0.01, 0.71] .09 [0.01, 0.71] .01 [-0.14, 0.36]	Std. Mean Difference IV, Random, 95% CI -0.5 Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI
teterogeneity: Tau ² = 0.00; Chi ² = 11 est for overall effect: Z = 1.12 (P = 0 otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = 0 (C) Moderate to vigorous PA (seli tudy or Subgroup differences: Chi ² = (C) Moderate to vigorous PA (seli ates et al [40], 2009 11,589 arrason et al [32], 2009 145,4 ing et al [42], 2020 103,4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) (D) Walking future of Subgroup Mean 4.1 Walking (self-reported) rederix et al [33], 2015 796 faddison et al [34], 2015 796 faddison et al [34], 2015 796 faddison et al [34], 2015 792 bubotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 3.35 (P = est for overall effect: Z = 3.35 (P = st for overall effect: Z = 0.36 (P = st for overall effect: Z = 3.35 (P = est for overall effect: Z = 0.36 (P = st for overall effect: Z = 0.37 (P = est for overall effect: Z = 3.35 (P = st for overall effect: Z = 0.00; Chi ² = 0 est for overall effect: Z = 0.88 (P =	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 2.412.24 \ 271 \ 1, \\ 118.8 \ 81 \\ 179.7 \ 123 \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{231} \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{pplicable} \\ \textbf{rt technology} \\ \textbf{technology} \\ \textbf{159} \\ \textbf{Total} \\ \textbf{967} \ 69 \\ \textbf{1698.28} \ 27 \\ \textbf{154} \\ 0.065, df = 2 \ (P = 0.5) \\ 0.0008) \\ \textbf{terventions with on} \\ 205.1 \ 123 \\ \textbf{123} \\ \textbf{123} \\ \textbf{0.38} \end{array}$	$\begin{array}{l} {} (12) \\ \textbf{020} \\ \textbf{020} \\ \textbf{7}; \ 1^2 = 46\% \\ \textbf{1005}, \ 1^2 = 87.1\% \\ \hline \textbf{Face-to-facc} \\ \textbf{Mean} & \textbf{Si} \\ \textbf{126.9} & 195. \\ \textbf{105.4} & 153. \\ \textbf{126.9} & 195. \\ \textbf{105.4} & 153. \\ \textbf{2}; \ 1^2 = 0\% \\ \hline \textbf{Face-to-facc} \\ \textbf{Mean} & \textbf{SD} \\ \textbf{1585} & \textbf{1,389.5} \\ \textbf{370;} \ 1^2 = 0\% \\ \hline \textbf{1585} & \textbf{1,389.5} \\ \textbf{377;} \ 1^2 = 0\% \\ \hline \textbf{15833} \\ \textbf{15834} \\ \textbf{15834} \\ \textbf{131.9} & \textbf{183.3} \\ \end{array}$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 244 10 10 24 10	Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 00.0% 0 8.8% 0.4 4.3% 0.1 4.3% 0.1	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .038 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.16, 0.61] .11 [-0.14, 0.36] .11 [-0.14, 0.36]	Face-to-face alone Smart technology include
eterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% CI) eterogeneity: Tau ² = 0.02; Chi ² = 12 est for overall effect: Z = 2.15 (P = C C) Moderate to Z = 2.15 (P = C C) Moderate to vigorous PA (sell tady or Subgroup differences: Chi ² = (C) Moderate to vigorous PA (sell tates et al (40), 2009 1.589 arnason et al [32], 2009 145,4 ing et al (42], 2020 103,4 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = diaddison et al [33], 2015 796 faddison et al [34], 2015 512, 3 ates et al (40), 2009 2,292 ubtotal (95% CI) eterogeneity: Tau ² = 0.00; Chi ² = est for overall effect: Z = 3.35 (P = 4.4.2 Walking (self-reported) – int ing et al [42], 2020 153.9 ubtotal (95% CI)	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{tabular} \\ tabul$	$Face-to-facMean SD(1); l^2 = 0\%(1); l^2 = 87.1\%Face-to-facMean SD(1); l^2 = 0\%(2); l^2 = 0\%(2); l^2 = 0\%(2); l^2 = 0\%(3); l^2 = 0\%(4); l^2 = 0\%($	1049 <u>D Total W</u> 5 23 7 99 5 122 244 10 244 10 244 10 244 10 244 10 0 244 10 10 244 10 10 244 10 244 10 244 10 244 10 23 8 161 55 000gy 122 44 122 12 122 12 122 12 124 10 122 12 124 10 123 12 124 10 124 10 125 12 126 12 127 12 128 128 12 128 128 128 128 128 128 128 128 128 128	Std. N Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 10.5% 0 37.7% 0 2.3% 0 8.3% 0.4 4.3% 0.1 0.0% 0	0.17 [0.02, 0.32] 0.17 [0.02, 0.32] 106 [-0.49, 0.62] 106 [-0.49, 0.62] 11 [-0.18, 0.41] 101 [-0.26, 0.24] 04 [-0.14, 0.22] 04 [-0.14, 0.22] 104 [-0.14, 0.22] 11 [-0.14, 0.72] 138 [0.04, 0.72] 138 [0.04, 0.72] 138 [0.04, 0.72] 138 [0.04, 0.72] 14 [-0.12, 1.01] 15 [0.16, 0.61] 11 [-0.14, 0.36] 11 [-0.14, 0.36] 126 [0.10, 0.43]	Std. Mean Difference IV, Random, 95% CI Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI Std. Mean Difference IV, Random, 95% CI
leterogeneity: Tau ² = 0.00; Chi ² = 1; est for overall effect: Z = 1.12 (P = C otal (95% C)) leterogeneity: Tau ² = 0.02; Chi ² = 11 est for overall effect: Z = 2.15 (P = C est for subgroup differences: Chi ² = (C) Moderate to vigorous PA (sell tudy or Subgroup mean test et al (40, 2009 1.589 ; arnason et al [32], 2009 145.4 ing et al [42], 2020 103.4 ates et al (40, 2009 145.4 ing et al [42], 2020 103.4 ubtotal (95% C)) leterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = otal 95% C) leterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 0.46 (P = est for subgroup Mean tudy or Subgroup Mean tudy or Subgroup Mean tudy or Subgroup Mean tudy or Subgroup Mean t.4.1 Walking (self-reported) rederix et al [33], 2015 512.3 ates et al [40], 2009 2.292 ubtotal (95% C) leterogeneity: Tau ² = 0.00; Chi ² = 0 est for overall effect: Z = 3.35 (P = est for overall effect: Z = 0.38 (P = set for overall effect: Z = 0.08 (P = est for overall effect: Z = 0.00; Chi ² = 0 ist for overall effect: Z = 0.00; Chi ² = 0 est for overall effect: Z = 0.08 (P = est for overall effect: Z = 0.00; Chi ² = 0 ist for overall effect: Z = 0.00; Chi ² = 0 ist for overall effect: Z = 0.00; Chi ² = 0 ist for overall effect: Z = 0.00; Chi ² = 0 ist for overall effect: Z = 0.08 (P =	$\begin{array}{c} 72, df = 2 \ (P = 0.42) \\ 0.26) \\ 1 \\ 2.91, df = 7 \ (P = 0.0) \\ 0.03) \\ 7.77, df = 1 \ (P = 0.0) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{technology} \\ \textbf{technology} \\ 12, 412, 24 \\ 2412, 24 \\ 2412, 24 \\ 211, 128 \\ 179, 7 \\ 123 \\ 123 \\ 0.40, df = 2 \ (P = 0.82) \\ 0.65) \\ \textbf{gorous PA} \\ \textbf{technology} \\ \textbf{splitzer} \\ spl$	(1, 1) = 0% $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 2) = 0%$ $(1, 3) = 0$ $(1, 2) = 0%$ $(1, 3) = 0$ $(1$	1049 D Total W 5 23 7 99 5 122 244 10 244 10 244 10 244 10 244 10 10 244 10 10 244 10 10 244 10 244 10	Std. N Veight IV. 10.5% 0 37.7% 0 51.8% -0 00.0% 0 00.0% 0 00.0% 0 8.8% 0.4 5.7% 0. 4.3% 0.1 0.0% 0.	0.17 [0.02, 0.32] tean Difference Random, 95% CI .06 [-0.49, 0.62] .11 [-0.18, 0.41] .01 [-0.26, 0.24] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .04 [-0.14, 0.22] .03 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.04, 0.72] .38 [0.16, 0.61] .1 [-0.14, 0.36] 1 [-0.14, 0.36] .26 [0.10, 0.43]	Std. Mean Difference IV, Random, 95% CI Face-to-face alone Smart technology include Std. Mean Difference IV, Random, 95% CI Std. Mean Difference IV, Random, 95% CI

Subgroup Analyses

Smart Technology Components

We completed meta-analyses for subgroups according to the type of smart technology that was used for steps per day and total PA scores (Multimedia Appendix 1, section 5). Studies assessing steps per day used pedometers [27,30,39,40], smartphone apps [36,41], telerehabilitation [28,42], and wearable activity trackers in their interventions [35,38]. When

https://www.jmir.org/2022/10/e36134

XSL•FO

examining the effects of each intervention component separately, only smartphone apps (MD 3.07, 95% CI 0.5-5.55) and wearable activity trackers (MD 2.29, 95% CI 1.44-3.13) showed significant improvements in favor of smart technology interventions. Smart technology interventions for studies that assessed total PA included pedometers [43], telerehabilitation [42], websites [45], smartphone apps [36,41], and interventions including multiple smart technology components [33,34,37]. In the subgroup meta-analyses, smartphone apps showed

significant improvements in total PA scores compared with face-to-face alone (SMD 0.37, 95% CI 0.10-0.63), and multicomponent interventions favored smart technology, but the effect was not statistically significant (SMD 0.23, 95% CI -0.05 to 0.51).

Smart Technology Alone

There was a large variability in the components making up smart technology interventions in the included studies. Only 4 RCTs (n=1701) evaluated the effect of an entirely smart technology alone intervention (ie, did not include any in-person

consultations) versus face-to-face alone [28,37,42,45]. Subgroup analyses were performed for both steps per day and total PA scores. For both outcomes, the pooled results were not significant and did not appear to favor either intervention (Figure 2).

The evidence for the effect of smart technology interventions on PA was judged to be very low based on the GRADE criteria (Figure 3). Therefore, our confidence in the effect estimate is limited, and the true effect is likely to be different from the estimated effect.

Figure 3. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) summary of findings table.

Outcomes	Number of participants	Number of studies	Certainty of evidence	Comments			
			(GRADE)				
Physical Activity							
Steps per day	877	12/18 (67%)	000	A total of 11 studies showed improvement in steps per day, favoring smart technology interventions. Certainty of evidence is very low owing to risk of bias, inconsistency, indirectness, and imprecision.			
Self-reported total physical activity	2036	9/18 (50%)	000	A total of 6 studies showed increased levels of total physical activity, favoring smart technology interventions. Certainty of evidence is low owing to high risk of bias, indirectness, and imprecision.			
Self-reported walking time	620	6/18 (33%)	⊕000	All 6 studies showed increased walking time, favoring the smart technology interventions. Certainty of evidence is very low owing to risk of bias, indirectness, and imprecision.			
Moderate to vigorous physical activity	585	6/18 (33%)	⊕000	A total of 4 studies showed increased time in moderate to vigorous physical activity, favoring smart technology interventions. Certainty of evidence is very low owing to risk of bias, indirectness, and imprecision.			
Physical Function	1						
Physical function – 6MWT ^a	347	6/18 (33%)	0000	A total of 2 studies showed improvements in 6MWT, favoring smart technology interventions. Certainty of evidence is low owing to high risk of bias, indirectness, and imprecision.			
Physical function – 30- second sit-to- stand test	184	3/18 (17%)	0000	There was no difference in the sit-to-stand outcomes between smart technology interventions and controls. Certainty of evidence is moderate owing to risk of bias and imprecision.			
Adherence	434	9/18 (50%)	⊕000	A total of 8 studies demonstrated good adherence to the smart technology interventions, with 1 study unable to determine owing to missing data. Certainty of evidence very low due to risk of bias, indirectness, and imprecision.			
Secondary Outcomes							
Quality of life	442	6/18 (33%)	⊕000	A total of 2 studies showed improvements in quality of life, favoring smart technology. Certainty of evidence very low due to risk of bias, indirectness, and imprecision.			
Depression	150	2/18 (1%)	000	Both studies showed improvements in depression scales favouring smart-technology interventions. Certainty of evidence very low due to risk of bias, indirectness, and imprecision.			



Physical Function

Overview

Of 19 studies, 10 (53%) evaluated some aspects of physical function. The most common performance-based measures were the 6-minute walk test (6-MWT) [28-30,35,41] and the 30-second sit-to-stand test [27,28,39]. The remaining 13 measures were only included in 1 or 2 studies (eg, 4-meter gait speed [34], short physical performance battery [34], timed stair climbing [35], peak VO₂ [14,39], hand grip strength [31,34],

maximal inspiratory and expiratory force [29], and quadriceps force) [29,35] and therefore were not pooled (Figure 4). In total, 5 RCTs were pooled in a random effects meta-analysis for 6-MWT including 327 participants, with a MD of -1.77 m (95% CI -2.63 to -0.90) [28,29,32,34,38]. Furthermore, 3 studies (n=184) that used the 30-second sit-to-stand test found no significant difference between interventions (SMD -0.37, 95% CI -1.66 to 0.92). The sensitivity analysis for the 6-MWT test included 3 studies (n=267). After removing those with a high risk of bias, the difference was not statistically significant (MD -3.26, 95% CI -19.97 to 13.45; Multimedia Appendix 1).

Figure 4. Meta-analysis of smart technology versus face-to-face alone for physical function. 6MWT- 6-minute walk test. (A) 6MWT



(B) 30-second sit-to-stand test



Notes: green squares represent individual study effect sizes; black diamonds represent pooled effect sizes of subgroups and total effect size.

Subgroup Analyses

Smart Technology Intervention Components

We conducted additional meta-analyses on 5 studies that included the 6-MWT as an outcome by type of smart technology intervention component: pedometers [29,30], smartphone apps [41], telerehabilitation [28], and wearable activity trackers [35]. We examined the effects of pedometer interventions on the 6-MWT on their own. There was a nonsignificant MD (4.40, 95% CI –25.28 to 34.07). Smart technology components included in the 3 studies with the 30-second sit-to-stand test were pedometers [27,39] and telerehabilitation [28]. The findings were nonsignificant for pedometers compared with face-to-face alone with an MD of -0.60 (95% CI -2.14 to 0.94).

```
https://www.jmir.org/2022/10/e36134
```

RenderX

Complete results for these meta-analyses are available in section 6 of Multimedia Appendix 1.

Smart Technology Alone

Only 1 study (n=134) examined a smart technology intervention alone using telerehabilitation (video conferencing) [28]. For both the 6-MWT and the 30-second sit-to-stand test, results in this study favored the face-to-face intervention.

The evidence for the effect of smart technology on the 6-MWT and the 30-second sit-to-stand test was judged to be very low based on the GRADE criteria. Therefore, our confidence in the effect estimates is limited, and the true effect may be substantially different from the estimated effect.

D'Amore et al

Adherence Rates

A total of 10 studies did not report adherence rates [30,32-34,37,38,40,43,45]. Two studies reported overall adherence to the intervention [28,42], and 7 studies reported adherence to the components of the intervention [27,29,31,35,39,41,44]. Overall, across the available studies, adherence rates to smart technology interventions ranged from 64.8% [42] to 95.5% [27]. Adherence to specific smart technology interventions ranged from 76% [39] to 95.5% [27], and telerehabilitation ranged from 64.8% [32] to 85% [28]. The adherence to face-to-face interventions ranged from 64% [28] to 100% [41].

Secondary Outcomes

Three studies measured depression using different scales, including the Hospital Anxiety and Depression Scale [28], Beck Depression Inventory [27], and Care Depression Instrument [37]. We pooled data from 2 RCTs for a random effects meta-analysis, which showed no significant difference between interventions that included smart technology and face-to-face alone (SMD 0.09, 95% CI -0.23 to 0.41) [27,28]. Furthermore, 6 studies measured HRQoL using the Clinical COPD Questionnaire [28,31], St George's Respiratory Questionnaire [27,30], HeartQoL global score [33], and Chronic Respiratory Disease Questionnaire [29]. A meta-analysis of 6 studies demonstrated a significant SMD (0.31, 95% CI 0.11-0.51) in favor of smart technology interventions. For HRQoL, we completed a subgroup analysis by smart technology component; multicomponent interventions (n=2; SMD 0.35, 95% CI 0.05-0.66) showed significant improvements compared with face-to-face alone, but pedometers did not (n=3; SMD 0.04, 95% CI –0.49 to 0.57). After performing a sensitivity analysis excluding studies with a high risk of bias, our results did not change the significance or direction of results. Only 1 study examined anxiety using the Hospital Anxiety and Depression Scale and demonstrated an improvement in favor of smart technology at the first follow-up [28]. Meta-analyses for secondary outcomes are available in Multimedia Appendix 1.

Discussion

Principal Findings

PA is integral to reducing age-related illness and disability. This review of 19 studies involving 3455 patients found that interventions that include smart technology may improve steps per day, total PA, walking, and HRQoL in older adults. Although the overall quality and certainty of the evidence were judged to be very low and more precise estimates will need to be obtained, our results may have important implications for research and practice on PA promotion, especially in the context of the COVID-19 pandemic and public health restrictions.

Among the included studies, we found that most (n=15) smart technology interventions used multiple components with intervention groups also receiving a face-to-face component. One of the challenges of multicomponent interventions is that it limits our understanding of the effectiveness of smart technology alone. For example, intervention and control groups in several studies received usual care, with the only difference

```
https://www.jmir.org/2022/10/e36134
```

between groups being the addition of a pedometer or wearable activity tracker [29,38-40]. Of the 4 studies examining smart technology alone, 2 examined the effect on steps per day; our subgroup analysis found a nonsignificant difference of 260 steps per day favoring smart technology [28,42]. Notably, the results from these 2 studies were contradictory, with Hansen et al [28] reporting that face-to-face interventions were more effective. However, they evaluated patients with severe COPD and reported a decline in PA for both groups over the course of the study. This may be caused, in part, by the progressive nature of COPD or by the short length of the intervention at only 10 weeks [28]. In line with our meta-analysis for steps per day, the 3 RCTs examining the effect of smart technology alone on total PA showed a small, nonsignificant effect favoring smart technology [37,42,45]. It will be important for future work to determine whether smart technology on its own is more, less, or as effective as face-to-face interventions. This is especially important during the COVID-19 pandemic, as in-person contacts should be limited to minimize the risk of transmission. Conversely, if smart technology interventions alone are less effective, it will be important to revert to including some type of face-to-face component as soon as it is safe and feasible.

Patient-important outcomes were not well represented in our included studies, which highlights an important gap in the design and reporting of smart technology interventions. Among 19 studies, only 7 (37%) unique studies reported on patient-important outcomes: 6 reported on HRQoL [27-31,33], 3 on depression [27,28,37], and 1 on anxiety [28]. Evidence has demonstrated associations between PA levels and mental health and quality of life in older adults [51]. Therefore, it is vital that research includes these measures to further our understanding of the magnitude and direction of these relationships. This is timely as we have seen the prevalence of depression and anxiety increasing over the last 2 years with the pandemic and public health restrictions [52]. Older adults have been shown to be at an increased risk for anxiety [52]. In addition to the lack of patient-important outcomes, we found that data on intervention adherence were largely missing or inconsistently reported. This leads to several challenges, including understanding the acceptability of these interventions for older adults and interpreting results of the primary studies. For example, if adherence to the intervention was poor, it would be difficult to appreciate if the differences (or lack thereof) between groups were because of intervention failure or implementation failure. The issue of acceptability is also crucial, particularly considering that the current literature on the usability of technology in this population is limited.

Our results suggest that the type of smart technology used for PA interventions may influence the effectiveness of the intervention. We found that studies that used smartphone apps led to significant improvements in steps per day and total PA scores [53]. Other systematic reviews examining the effectiveness of mobile phone interventions in adults aged >18 years and >50 years and older adults (>65 years) have shown mixed evidence for improving PA [53-55]. Potential reasons for these discordant results may be the diversity of interventions within control groups, small sample sizes, and moderate to high levels of heterogeneity across studies [53,54]. We also found

XSL•FO RenderX

that wearable activity trackers significantly improved the number of steps per day. Researchers should consider the type of smart technology in conjunction with the PA goals and the population to achieve the best outcome. Further research is warranted to determine the optimal types of smart technology interventions for older adults.

The existing literature has several limitations that warrant future research. Our findings are based on very low quality of evidence, as per the GRADE criteria. All included studies had some concerns or a high risk of bias, most commonly because of missingness of outcomes, lack of intention-to-treat analyses, inadequate allocation concealment, and lack of prespecified statistical analyses or protocols. The variability in populations, smart technology interventions, control group interventions, and outcomes among studies are major contributing factors to the large degree of statistical heterogeneity. Furthermore, most studies used multiple components, making it difficult to assess which parts may have contributed to differences between groups or, conversely, if additive components may have diluted a potentially effective intervention. Importantly, 79% (15/19) of the studies included an element of face-to-face interaction in the intervention group, making it difficult to evaluate the effectiveness of smart technology alone. Due to the limited number of studies and small sample sizes, there is a need to group studies and smart technologies broadly to have sufficient sample sizes to conduct meta-analyses. Given that different smart technologies can be used for different intervention components, it may be difficult to apply our findings in practice when designing interventions. Although we conducted subgroup analyses where there were sufficient data, there is a need for additional research comparing different types of smart technologies for supporting specific PA interventions in older adults [18,19,23]. Finally, our results may have been influenced by the high risk of performance bias caused by the impracticability of blinding therapists and participants owing

to the nature of the interventions. Future research should focus on minimizing the risk of bias, evaluating individual smart technology components and smart technology alone, and including standardized control groups. Improved reporting of control group interventions may also assist with interpretation of results.

This review also has some limitations. We did not include gray literature owing to a lack of central sources to identify and retrieve these citations [56]. In addition, we excluded studies published in languages other than English because of the feasibility of the review. Therefore, our cohort of studies may not represent the entirety of the literature. This review has several important strengths. To the best of our knowledge, this is the first study to attempt to compare smart technology interventions specifically with face-to-face interventions, which is critical for determining their effectiveness compared with traditional modes of delivery. In addition, we published our peer-reviewed protocol, and we developed and conducted our search in collaboration with a health research librarian.

Conclusions

In the context of substantial heterogeneity and very low quality of evidence, our results suggest that PA interventions that include smart technology components may significantly improve steps per day and total PA in community-dwelling older adults. Subgroup analyses showed that smartphone apps and wearable activity trackers seem to be the most effective smart technology, which may be helpful for health care practitioners when determining appropriate methods of remote PA promotion. When comparing smart technology alone with face-to-face alone, there were few studies with discordant results and no significant differences between groups. The results should be interpreted with caution given the challenges with the existing literature cited in the discussion.

Acknowledgments

JCR was funded by the Canadian Frailty Network Interdisciplinary Fellowship and MKB holds a Tier 2 Canada Research Chair in Mobility, Aging and Chronic Disease.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Description of data: search strategies, full text exclusion reasons, detailed intervention reasons, risk of bias summary, physical activity meta-analyses, and secondary outcome meta-analyses. [DOC File, 6397 KB-Multimedia Appendix 1]

References

- World Population Ageing 2017 Highlights (ST/ESA/SER.A/397). Department of Economic and Social Affairs, United Nations. 2017. URL: <u>https://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2017_Highlights.</u> <u>pdf</u> [accessed 2021-12-09]
- 2. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for Americans. JAMA 2018 Nov 20;320(19):2020-2028. [doi: 10.1001/jama.2018.14854] [Medline: 30418471]
- 3. WHO guidelines on physical activity and sedentary behaviour. World Health Organization. Geneva, Switzerland: World Health Organization; 2020 Nov 25. URL: <u>https://www.who.int/publications/i/item/9789240015128</u> [accessed 2021-12-09]

- 4. Gomes M, Figueiredo D, Teixeira L, Poveda V, Paúl C, Santos-Silva A, et al. Physical inactivity among older adults across Europe based on the SHARE database. Age Ageing 2017 Jan 20;46(1):71-77 [FREE Full text] [doi: 10.1093/ageing/afw165] [Medline: 28181637]
- Kohl 3rd HW, Craig CL, Lambert EV, Inoue S, Alkandari JR, Leetongin G, Lancet Physical Activity Series Working Group. The pandemic of physical inactivity: global action for public health. Lancet 2012 Jul 21;380(9838):294-305. [doi: 10.1016/S0140-6736(12)60898-8] [Medline: 22818941]
- Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012 Jul 21;380(9838):219-229 [FREE Full text] [doi: 10.1016/S0140-6736(12)61031-9] [Medline: 22818936]
- Cunningham C, O' Sullivan R, Caserotti P, Tully MA. Consequences of physical inactivity in older adults: a systematic review of reviews and meta-analyses. Scand J Med Sci Sports 2020 May;30(5):816-827. [doi: <u>10.1111/sms.13616</u>] [Medline: <u>32020713</u>]
- 8. World Health Organization. Global Action Plan on Physical Activity 2018-2030: More Active People for a Healthier World. Geneva, Switzerland: World Health Organization; 2019.
- 9. WHO Coronavirus Disease (COVID-19) Dashboard. Secondary WHO Coronavirus Disease (COVID-19) Dashboard 2021. World Health Organization. 2021. URL: <u>https://covid19.who.int</u> [accessed 2021-12-09]
- Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020 Apr;76:71-76 [FREE Full text] [doi: 10.1016/j.ijsu.2020.02.034] [Medline: 32112977]
- 11. D'Adamo H, Yoshikawa T, Ouslander JG. Coronavirus disease 2019 in geriatrics and long-term care: the ABCDs of COVID-19. J Am Geriatr Soc 2020 May;68(5):912-917. [doi: <u>10.1111/jgs.16445</u>] [Medline: <u>32212386</u>]
- 12. Stockwell S, Trott M, Tully M, Shin J, Barnett Y, Butler L, et al. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review. BMJ Open Sport Exerc Med 2021 Feb 1;7(1):e000960 [FREE Full text] [doi: 10.1136/bmjsem-2020-000960] [Medline: 34192010]
- Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 2012 Jul 21;380(9838):247-257. [doi: 10.1016/S0140-6736(12)60646-1] [Medline: 22818937]
- 14. Global diffusion of eHealth: making universal health coverage achievable: report of the third global survey on eHealth. License: CC BY-NC-SA 3.0 IGO. World Health Organization. 2016. URL: <u>https://apps.who.int/iris/handle/10665/252529</u> [accessed 2021-12-09]
- 15. Mönninghoff A, Kramer JN, Hess AJ, Ismailova K, Teepe GW, Tudor Car L, et al. Long-term effectiveness of mHealth physical activity interventions: systematic review and meta-analysis of randomized controlled trials. J Med Internet Res 2021 Apr 30;23(4):e26699 [FREE Full text] [doi: 10.2196/26699] [Medline: 33811021]
- Orlando JF, Beard M, Kumar S. Systematic review of patient and caregivers' satisfaction with telehealth videoconferencing as a mode of service delivery in managing patients' health. PLoS One 2019 Aug 30;14(8):e0221848 [FREE Full text] [doi: 10.1371/journal.pone.0221848] [Medline: <u>31469865</u>]
- 17. mHealth: new horizons for health through mobile technologies: second global survey on eHealth. World Health Organization. 2011. URL: <u>https://apps.who.int/iris/bitstream/handle/10665/44607/9789241564250_eng.pdf?sequence=1&isAllowed=y</u> [accessed 2021-06-15]
- Núñez de Arenas-Arroyo S, Cavero-Redondo I, Alvarez-Bueno C, Sequí-Domínguez I, Reina-Gutiérrez S, Martínez-Vizcaíno V. Effect of eHealth to increase physical activity in healthy adults over 55 years: a systematic review and meta-analysis. Scand J Med Sci Sports 2021 Apr;31(4):776-789. [doi: 10.1111/sms.13903] [Medline: 33280182]
- Jonkman NH, van Schooten KS, Maier AB, Pijnappels M. eHealth interventions to promote objectively measured physical activity in community-dwelling older people. Maturitas 2018 Jul;113:32-39. [doi: <u>10.1016/j.maturitas.2018.04.010</u>] [Medline: <u>29903646</u>]
- 20. Liu JY, Kor PP, Chan CP, Kwan RY, Sze-Ki D. The effectiveness of a wearable activity tracker (WAT)-based intervention to improve physical activity levels in sedentary older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2020 Jul 26;91:104211. [doi: 10.1016/j.archger.2020.104211] [Medline: 32739713]
- 21. Sohaib Aslam A, van Luenen S, Aslam S, van Bodegom D, Chavannes NH. A systematic review on the use of mHealth to increase physical activity in older people. Clinical eHealth 2020;3:31-39 [FREE Full text] [doi: 10.1016/j.ceh.2020.04.002]
- Franssen WM, Franssen GH, Spaas J, Solmi F, Eijnde BO. Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials. Int J Behav Nutr Phys Act 2020 May 11;17(1):57 [FREE Full text] [doi: 10.1186/s12966-020-00955-2] [Medline: 32393357]
- Muellmann S, Forberger S, Möllers T, Bröring E, Zeeb H, Pischke CR. Effectiveness of eHealth interventions for the promotion of physical activity in older adults: a systematic review. Prev Med 2018 Mar;108:93-110. [doi: 10.1016/j.ypmed.2017.12.026] [Medline: 29289643]



- 24. D'Amore C, Reid JC, Chan M, Fan S, Huang A, Louie J, et al. Smart technology vs. face-to-face physical activity interventions in older adults: a systematic review protocol. JBI Evid Synth 2021 Sep 07;19(10):2801-2812. [doi: <u>10.11124/JBIES-21-00072</u>] [Medline: <u>34494613</u>]
- 25. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015 Jan 02;350:g7647 [FREE Full text] [doi: 10.1136/bmj.g7647] [Medline: 25555855]
- McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016 Jul;75:40-46 [FREE Full text] [doi: 10.1016/j.jclinepi.2016.01.021] [Medline: 27005575]
- 27. de Blok BM, de Greef MH, ten Hacken NH, Sprenger SR, Postema K, Wempe JB. The effects of a lifestyle physical activity counseling program with feedback of a pedometer during pulmonary rehabilitation in patients with COPD: a pilot study. Patient Educ Couns 2006 Apr;61(1):48-55. [doi: 10.1016/j.pec.2005.02.005] [Medline: 16455222]
- Hansen H, Bieler T, Beyer N, Kallemose T, Wilcke JT, Østergaard LM, et al. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial. Thorax 2020 May;75(5):413-421 [FREE Full text] [doi: 10.1136/thoraxjnl-2019-214246] [Medline: 32229541]
- 29. Kawagoshi A, Kiyokawa N, Sugawara K, Takahashi H, Sakata S, Satake M, et al. Effects of low-intensity exercise and home-based pulmonary rehabilitation with pedometer feedback on physical activity in elderly patients with chronic obstructive pulmonary disease. Respir Med 2015 Mar;109(3):364-371 [FREE Full text] [doi: 10.1016/j.rmed.2015.01.008] [Medline: 25682543]
- Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, et al. Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur Respir J 2015 Feb;45(2):347-354 [FREE Full text] [doi: 10.1183/09031936.00084514] [Medline: 25261324]
- Tabak M, Vollenbroek-Hutten MM, van der Valk PD, van der Palen J, Hermens HJ. A telerehabilitation intervention for patients with Chronic Obstructive Pulmonary Disease: a randomized controlled pilot trial. Clin Rehabil 2014 Jun;28(6):582-591. [doi: 10.1177/0269215513512495] [Medline: 24293120]
- 32. Barnason S, Zimmerman L, Nieveen J, Schulz P, Miller C, Hertzog M, et al. Influence of a symptom management telehealth intervention on older adults' early recovery outcomes after coronary artery bypass surgery. Heart Lung 2009;38(5):364-376 [FREE Full text] [doi: 10.1016/j.hrtlng.2009.01.005] [Medline: 19755186]
- 33. Frederix I, Hansen D, Coninx K, Vandervoort P, Vandijck D, Hens N, et al. Medium-term effectiveness of a comprehensive Internet-based and patient-specific telerehabilitation program with text messaging support for cardiac patients: randomized controlled trial. J Med Internet Res 2015 Jul 23;17(7):e185 [FREE Full text] [doi: 10.2196/jmir.4799] [Medline: 26206311]
- 34. Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the HEART randomized controlled trial. Eur J Prev Cardiol 2015 Jun;22(6):701-709. [doi: 10.1177/2047487314535076] [Medline: 24817694]
- 35. Roberts LM, Jaeger BC, Baptista LC, Harper SA, Gardner AK, Jackson EA, et al. Wearable technology to reduce sedentary behavior and CVD risk in older adults: a pilot randomized clinical trial. Clin Interv Aging 2019 Oct 23;14:1817-1828 [FREE Full text] [doi: 10.2147/CIA.S222655] [Medline: 31695350]
- 36. Alonso-Domínguez R, Patino-Alonso MC, Sánchez-Aguadero N, García-Ortiz L, Recio-Rodríguez JI, Gómez-Marcos MA. Effect of a multifactorial intervention on the increase in physical activity in subjects with type 2 diabetes mellitus: a randomized clinical trial (EMID Study). Eur J Cardiovasc Nurs 2019 Jun;18(5):399-409. [doi: 10.1177/1474515119835048] [Medline: 30808196]
- 37. Weinstock RS, Brooks G, Palmas W, Morin PC, Teresi JA, Eimicke JP, et al. Lessened decline in physical activity and impairment of older adults with diabetes with telemedicine and pedometer use: results from the IDEATel study. Age Ageing 2011 Jan;40(1):98-105. [doi: 10.1093/ageing/afq147] [Medline: 21081539]
- Christiansen MB, Thoma LM, Master H, Voinier D, Schmitt LA, Ziegler ML, et al. Feasibility and preliminary outcomes of a physical therapist-administered physical activity intervention after total knee replacement. Arthritis Care Res (Hoboken) 2020 May;72(5):661-668 [FREE Full text] [doi: 10.1002/acr.23882] [Medline: 30908867]
- 39. Talbot LA, Gaines JM, Huynh TN, Metter EJ. A home-based pedometer-driven walking program to increase physical activity in older adults with osteoarthritis of the knee: a preliminary study. J Am Geriatr Soc 2003 Mar;51(3):387-392. [doi: 10.1046/j.1532-5415.2003.51113.x] [Medline: 12588583]
- 40. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care 2009 Aug;32(8):1404-1410 [FREE Full text] [doi: 10.2337/dc09-0130] [Medline: 19602539]
- 41. Kwan RY, Lee D, Lee PH, Tse M, Cheung DS, Thiamwong L, et al. Effects of an mHealth brisk walking intervention on increasing physical activity in older people with cognitive frailty: pilot randomized controlled trial. JMIR Mhealth Uhealth 2020 Jul 31;8(7):e16596 [FREE Full text] [doi: 10.2196/16596] [Medline: 32735218]
- 42. King AC, Campero MI, Sheats JL, Castro Sweet CM, Hauser ME, Garcia D, et al. Effects of counseling by peer human advisors vs computers to increase walking in underserved populations: the COMPASS randomized clinical trial. JAMA Intern Med 2020 Nov 01;180(11):1481-1490 [FREE Full text] [doi: 10.1001/jamainternmed.2020.4143] [Medline: 32986075]

- 43. Armit CM, Brown WJ, Ritchie CB, Trost SG. Promoting physical activity to older adults: a preliminary evaluation of three general practice-based strategies. J Sci Med Sport 2005 Dec;8(4):446-450. [doi: 10.1016/s1440-2440(05)80060-x] [Medline: 16602173]
- 44. Audsley S, Kendrick D, Logan P, Jones M, Orton E. A randomised feasibility study assessing an intervention to keep adults physically active after falls management exercise programmes end. Pilot Feasibility Stud 2020 Mar 7;6:37 [FREE Full text] [doi: 10.1186/s40814-020-00570-9] [Medline: 32161660]
- 45. Mouton A, Cloes M. Efficacy of a Web-based, center-based or combined physical activity intervention among older adults. Health Educ Res 2015 Jun;30(3):422-435. [doi: <u>10.1093/her/cyv012</u>] [Medline: <u>25772974</u>]
- 46. World Report on Ageing and Health. World Health Organization. 2015. URL: <u>https://apps.who.int/iris/bitstream/handle/10665/186463/9789240694811_eng.pdf?sequence=1&isAllowed=y</u> [accessed 2020-01-22]
- 47. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019 Aug 28;366:14898. [doi: 10.1136/bmj.14898] [Medline: 31462531]
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ 2008 May 03;336(7651):995-998 [FREE Full text] [doi: 10.1136/bmj.39490.551019.BE] [Medline: 18456631]
- 49. Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Hoboken, NJ, USA: Wiley Online Library; 2019.
- 50. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014 Dec 19;14:135 [FREE Full text] [doi: 10.1186/1471-2288-14-135] [Medline: 25524443]
- 51. Physical Activity Guidelines for Americans. 2nd edition. U.S. Department of Health and Human Services. 2018. URL: https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf [accessed 2021-03-22]
- 52. Pashazadeh Kan F, Raoofi S, Rafiei S, Khani S, Hosseinifard H, Tajik F, et al. A systematic review of the prevalence of anxiety among the general population during the COVID-19 pandemic. J Affect Disord 2021 Oct 01;293:391-398 [FREE Full text] [doi: 10.1016/j.jad.2021.06.073] [Medline: 34246947]
- 53. Romeo A, Edney S, Plotnikoff R, Curtis R, Ryan J, Sanders I, et al. Can smartphone apps increase physical activity? Systematic review and meta-analysis. J Med Internet Res 2019 Mar 19;21(3):e12053 [FREE Full text] [doi: 10.2196/12053] [Medline: 30888321]
- 54. Yorston LC, Kolt GS, Rosenkranz RR. Physical activity and physical function in older adults: the 45 and up study. J Am Geriatr Soc 2012 Apr;60(4):719-725. [doi: 10.1111/j.1532-5415.2012.03906.x] [Medline: 22486736]
- 55. McGarrigle L, Todd C. Promotion of physical activity in older people using mHealth and eHealth technologies: rapid review of reviews. J Med Internet Res 2020 Dec 29;22(12):e22201 [FREE Full text] [doi: 10.2196/22201] [Medline: 33372894]
- Mahood Q, Van Eerd D, Irvin E. Searching for grey literature for systematic reviews: challenges and benefits. Res Synth Methods 2014 Sep;5(3):221-234. [doi: <u>10.1002/jrsm.1106</u>] [Medline: <u>26052848</u>]

Abbreviations

COPD: chronic obstructive pulmonary disease
GRADE: Grading of Recommendations Assessment, Development, and Evaluation
HRQoL: health-related quality of life
MD: mean difference
PA: physical activity
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis
RCT: randomized controlled trial
SMD: standardized mean difference

Edited by G Eysenbach; submitted 03.01.22; peer-reviewed by A Videira-Silva, S De La Torre; comments to author 19.04.22; revised version received 31.05.22; accepted 09.08.22; published 31.10.22

Please cite as:

D'Amore C, Reid JC, Chan M, Fan S, Huang A, Louie J, Tran A, Chauvin S, Beauchamp MK Interventions Including Smart Technology Compared With Face-to-face Physical Activity Interventions in Older Adults: Systematic Review and Meta-analysis J Med Internet Res 2022;24(10):e36134 URL: https://www.jmir.org/2022/10/e36134 doi: 10.2196/36134 PMID:



©Cassandra D'Amore, Julie C Reid, Matthew Chan, Samuel Fan, Amanda Huang, Jonathan Louie, Andy Tran, Stephanie Chauvin, Marla K Beauchamp. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 31.10.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.